<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0085">
    <title>68 Ehrlichia, Anaplasma, and Related Intracellular Bacteria</title>
    <sect1 id="ch0085s0001">
      <title>68 Ehrlichia, Anaplasma, and Related Intracellular Bacteria</title>
      <anchor id="ch0085s0001a0001"/>
      <anchor id="ch0085s0000a0001"/>
      <para role="chapterAuthor"><phrase role="center">ELITZA S. THEEL AND BOBBI S. PRITT</phrase>
      </para>
      <para id="ch0085s0000p0001">The family<emphasis>Anaplasmataceae</emphasis> in the order <emphasis>Rickettsiales</emphasis> is composed of several genera of clinically significant bacteria encompassing both human and veterinary pathogens (<link linkend="ch0085s0000li0001">1</link>). Members of the genera <emphasis>Ehrlichia</emphasis> and <emphasis>Anaplasma</emphasis> are the best known, having been recognized as agents of veterinary importance for over a century and as human pathogens since 1987 (<link linkend="ch0085s0000li0002">2</link>, <link linkend="ch0085s0000li0003">3</link>). Members of the genera <emphasis>Neorickettsia</emphasis> and “<emphasis>Candidatus</emphasis> Neoehrlichia” are also known to be human and veterinary pathogens, and <emphasis>Wolbachia</emphasis> species are important endosymbionts of most human filarial parasites (<link linkend="ch0085s0000li0004">4</link>–<link linkend="ch0085s0000li0008">8</link>). This chapter focuses on the clinically relevant members of the <emphasis>Anaplasmataceae</emphasis>, with particular emphasis on <emphasis>Anaplasma phagocytophilum</emphasis> and <emphasis>Ehrlichia chaffeensis</emphasis>, the most common human pathogens in this family.</para>
      <sect2 id="ch0085s0001s0001">
        <title>TAXONOMY</title>
        <anchor id="ch0085s0001a0002"/>
        <anchor id="ch0085s0000a0002"/>
        <para id="ch0085s0000p0002"><emphasis>Anaplasmataceae</emphasis> is a family of obligately intracellular bacteria in the phylum <emphasis>Proteobacteria</emphasis>, section alpha (alphaproteobacteria), order <emphasis>Rickettsiales.</emphasis> Taxonomic classification of the rickettsias (<anchor id="ch0085s0000a0003"/><link linkend="ch0085s0000a0008">Fig. 1</link>) is based largely upon sequence analysis of the 16S rRNA gene and <emphasis>groEL</emphasis> (heat shock operon) (<link linkend="ch0085s0000li0001">1</link>) and, increasingly, on fully sequenced genomes (<link linkend="ch0085s0000li0009">9</link>). Phenotypic characteristics such as serologic cross-reactions, similarities among major immunodominant surface proteins, and cellular tropisms of these bacteria further support the phylogenetic approach (<link linkend="ch0085s0000li0010">10</link>, <link linkend="ch0085s0000li0011">11</link>). Minor sequence differences in 16S rRNA genes exist among some members of the <emphasis>Anaplasmataceae</emphasis> that are markers of their biological and ecological differences (<link linkend="ch0085s0000li0012">12</link>–<link linkend="ch0085s0000li0014">14</link>). For example, genetic variants of <emphasis>Anaplasma phagocytophilum</emphasis> exist among ticks and mammals in the northeastern United States and Europe, including some that probably do not cause disease in humans (<link linkend="ch0085s0000li0014">14</link>–<link linkend="ch0085s0000li0016">16</link>).</para>
      </sect2>
      <sect2 id="ch0085s0001s0002">
        <title>DESCRIPTION OF THE GENERA</title>
        <anchor id="ch0085s0001a0003"/>
        <anchor id="ch0085s0000a0004"/>
        <para id="ch0085s0000p0003">The family<emphasis>Anaplasmataceae</emphasis> contains small, nonmotile, pleomorphic, obligately intracellular bacteria that reside and propagate within host membrane-derived vacuoles in the host cell cytoplasm (<link linkend="ch0085s0000li0017">17</link>). The family is divided into at least 4 major clades representing separate genera: <emphasis>Ehrlichia, Anaplasma, Wolbachia</emphasis>, and <emphasis>Neorickettsia</emphasis> (<link linkend="ch0085s0000li0001">1</link>). Also in this family are “<emphasis>Candidatus</emphasis> Neoehrlichia,” which contains the human pathogen “<emphasis>Candidatus</emphasis> Neoehrlichia mikurensis” (<link linkend="ch0085s0000li0005">5</link>), and the potential genus <emphasis>Aegyptianella</emphasis> (currently listed as <emphasis>incertae sedis</emphasis> [uncertain taxonomic status]), which is most closely related to <emphasis>Anaplasma</emphasis> (<link linkend="ch0085s0000li0018">18</link>). Although they are Gram-negative organisms, some <emphasis>Anaplasmataceae</emphasis> members (e.g., <emphasis>Ehrlichia, Anaplasma</emphasis>, and <emphasis>Neorickettsia</emphasis> species) lack the genes necessary for lipopolysaccharide and peptidoglycan synthesis (<link linkend="ch0085s0000li0019">19</link>). <anchor id="ch0085s0000a0005"/><link linkend="ch0085s0000a0009">Table 1</link> describes important characteristics of select human and veterinary pathogens in the family <emphasis>Anaplasmataceae</emphasis>.</para>
        <para id="ch0085s0000p0004">All members of the<emphasis>Anaplasmataceae</emphasis> except <emphasis>Wolbachia</emphasis> spp. can multiply in vertebrate host cells and have at least one identified invertebrate vector host (<link linkend="ch0085s0000li0017">17</link>). The most commonly infected cells in vertebrate hosts are of hematopoietic origin; <emphasis>Anaplasma</emphasis> and <emphasis>Ehrlichia</emphasis> species infect cells of different hematopoietic lineages in different animal hosts, including granulocytes, monocytes, erythrocytes, and platelets (<link linkend="ch0085s0000li0017">17</link>). Other <emphasis>Ehrlichia</emphasis> species (e.g., <emphasis>Ehrlichia ruminantium</emphasis> and <emphasis>E. muris</emphasis>) also infect endothelial cells. <emphasis>Neorickettsia</emphasis> spp. most commonly infect mononuclear phagocytes but can also infect enterocytes in mammalian hosts, as well as various trematode and insect cells (<link linkend="ch0085s0000li0020">20</link>, <link linkend="ch0085s0000li0021">21</link>), while <emphasis>Wolbachia</emphasis> spp. infect arthropod and helminth gonadal cells (<link linkend="ch0085s0000li0022">22</link>–<link linkend="ch0085s0000li0024">24</link>). Recently, “<emphasis>Ca.</emphasis> Neoehrlichia mikurensis” was cultivated in human endothelial cell lines derived from the dermal microvasculature and pulmonary artery, which may indicate its <emphasis>in vivo</emphasis> target cell type (<link linkend="ch0085s0000li0025">25</link>).</para>
        <para id="ch0085s0000p0005">The<emphasis>Anaplasmataceae</emphasis> gain entry to the host cells through adhesion and endocytosis. As they propagate within vacuoles, they form mulberry-like clusters referred to as morulae (L. <emphasis>morum</emphasis>, mulberry) (<anchor id="ch0085s0000a0006"/><link linkend="ch0085s0000a0012">Fig. 2</link>), which are visible by light microscopy (<link linkend="ch0085s0000li0017">17</link>). Continued multiplication eventually results in cell lysis or exocytosis and release of bacteria, allowing continued infection of other competent cells (<link linkend="ch0085s0000li0026">26</link>). Characteristics of the cytoplasmic vacuole, including its relationship to the host cell mitochondria and endoplasmic reticulum, number of enclosed bacteria, and whether the bacteria are encompassed in a fibrillary matrix, vary by genus (<link linkend="ch0085s0000li0008">8</link>, <link linkend="ch0085s0000li0017">17</link>, <link linkend="ch0085s0000li0027">27</link>–<link linkend="ch0085s0000li0029">29</link>).</para>
        <para id="ch0085s0000p0006">As seen in transmission electron-microscopic studies,<emphasis>Anaplasma, Ehrlichia</emphasis>, and <emphasis>Neorickettsia</emphasis> species have two distinct morphologic forms: a small, compact dense-core form measuring 0.2 to 0.4 μm and a larger reticulate body (<emphasis>Anaplasma</emphasis> and <emphasis>Ehrlichia</emphasis>) or “lighter” form (<emphasis>Neorickettsia</emphasis>) measuring 0.8 to 1.5 μm (<link linkend="ch0085s0000li0027">27</link>). The infective dense-core forms of <emphasis>Anaplasma</emphasis> and <emphasis>Ehrlichia</emphasis> species differentially express specific ligands on their surface which enable cell adhesion and facilitate endocytosis. These ligands are not present on the metabolically active reticulate forms. Both dense-core and reticulate forms can be found within vacuoles and are capable of binary fission; this suggests that there is asynchronous development of infectious from noninfectious forms (<link linkend="ch0085s0000li0028">28</link>). <emphasis>Wolbachia</emphasis> species also exhibit pleomorphic morphology within infected hosts, appearing as small coccoid forms (0.25 to 1 μm in diameter) and ellipsoidal forms (0.5 to 1.3 μm long) (<link linkend="ch0085s0000li0023">23</link>). “<emphasis>Ca.</emphasis> Neoehrlichia mikurensis” has been observed as small cocci within membrane-bound cytoplasmic inclusions of endothelial cells of infected rodents (<link linkend="ch0085s0000li0005">5</link>).</para>
        <anchor id="ch0085s0000a0007"/>
        <beginpage pagenum="1295"/>
        <figure id="ch0085s0000f0001"><title><phrase role="figureLabel"><anchor id="ch0085s0000a0008"/><link linkend="ch0085s0000a0003">FIGURE 1</link></phrase> Neighbor-joining phylogenetic tree inferred from 16S rRNA gene sequences of selected <emphasis>Ehrlichia</emphasis>, “<emphasis>Candidatus</emphasis> Neoehrlichia,” <emphasis>Anaplasma, Neorickettsia</emphasis>, and <emphasis>Wolbachia</emphasis> spp. The evolutionary distances were computed using the Tamura-Nei model. <emphasis>Rickettsia rickettsii</emphasis> was used as the outgroup, and the bootstrap values for 1,000 replicates are displayed at the nodes. The scale bar represents substitutions per nucleotide position. Image courtesy of Sandor Karpathy.</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0085f04.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
        <para id="ch0085s0000p0007">Like other rickettsiae, members of the<emphasis>Anaplasmataceae</emphasis> have a reduced genome size and rely on host cell machinery for survival. Whole-genome shotgun sequencing of more than 75 <emphasis>Anaplasmataceae</emphasis> members has shown that genomes range from 0.86 Mb in <emphasis>Neorickettsia sennetsu</emphasis> to 1.18 Mb in <emphasis>Ehrlichia chaffeensis</emphasis> and 1.77 Mb in <emphasis>Anaplasma phagocytophilum</emphasis> (<link linkend="ch0085s0000li0019">19</link>). While this study did not include <emphasis>Wolbachia</emphasis> genomes, a recent review demonstrated significant genome size variability, ranging from 0.44 to 3.09 Mb (<link linkend="ch0085s0000li0024">24</link>). Genome sequencing identifies a low G+C content common to endosymbionts (except for <emphasis>Anaplasma marginale</emphasis>) and a large proportion of noncoding sequences (<link linkend="ch0085s0000li0019">19</link>). In contrast to the reductive evolution seen in other intracellular bacteria, <emphasis>Anaplasmataceae</emphasis> prokaryotes have many paralogous genes, which document partial gene duplication events (<link linkend="ch0085s0000li0019">19</link>). Active duplication of tandemly repeated sequences likely results in new genes encoding outer membrane proteins, leading to antigenic variation, immune evasion, and thereby enhanced survival. The <emphasis>Anaplasmataceae</emphasis> also possess partially duplicated genes that encode an anomalous type IV secretion system that most likely contributes to virulence, perhaps by transport of effectors into the host cell or by DNA uptake or in conjugation (<link linkend="ch0085s0000li0030">30</link>).</para>
        <table id="ch0085s0000t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0085s0000a0009"/><link linkend="ch0085s0000a0005">TABLE 1</link></phrase></emphasis> Selected features of <emphasis>Ehrlichia, Anaplasma, Neorickettsia</emphasis>, “<emphasis>Candidatus</emphasis> Neoehrlichia mikurensis,” and <emphasis>Aegyptianella</emphasis> species of human and veterinary interest<superscript><emphasis><anchor id="ch0085s0000a0010"/><link linkend="ch0085s0000a0011">a</link></emphasis></superscript>
</title>
          
          <tgroup cols="7">
            <tbody>
              <row>
                <entry><phrase role="center">Organism</phrase>
                </entry>
                <entry><phrase role="center">Vector(s)</phrase>
                </entry>
                <entry><phrase role="center">Geographic distribution</phrase>
                </entry>
                <entry><phrase role="center">Disease</phrase>
                </entry>
                <entry><phrase role="center">Host(s) developing disease</phrase>
                </entry>
                <entry><phrase role="center">Infected cell type(s)</phrase>
                </entry>
                <entry><phrase role="center">Reservoir host(s)</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Anaplasma</emphasis>
                  </phrase>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Anaplasma phagocytophilum</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes persulcatus group, Haemaphysalis concinna, H. longicornis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Asia, Europe, North America</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>EGE, tick-borne fever (ruminants), human anaplasmosis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Humans, horses, ruminants, dogs</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Granulocytes (neutrophils, eosinophils, basophils)</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Small mammals (white-footed mice, chipmunks, voles), deer, sheep, cattle, goats</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Anaplasma marginale, A. centrale, A. ovis, “A. capr</emphasis>
                    <superscript>
                      <emphasis>
                        <link linkend="ch0085s0000a0011">a</link>
                      </emphasis>
                    </superscript>
                    <emphasis>”</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Several ticks and mechanical vectors</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Africa, Middle East, Europe, North America, Asia</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ruminant and human anaplasmosis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Cattle, other ruminants, humans (Asia)</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Erythrocytes</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ruminants, wild cervids?</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Anaplasma platys</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Rhipicephalus sanguineus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>U.S., Venezuela</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Canine cyclic thrombocytopenia</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Dogs</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Platelets</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Canids, ruminants?</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>“Anaplasma bovis”</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Several; includes Rhipicephalus appendiculatus, Amblyomma variegatum</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Africa, Middle East, North America, South America</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Bovine ehrlichiosis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Cattle</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Monocytes</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ruminants? Rabbits?</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Ehrlichia</emphasis>
                  </phrase>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Ehrlichia chaffeensis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Amblyomma americanum</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>U.S., Venezuela, Brazil</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>E. chaffeensis ehrlichiosis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Humans Dogs</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Monocytes</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>White-tailed deer, domestic dogs, rodents, birds?</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Ehrlichia ewingii</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Amblyomma americanum</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>U.S.</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>CGE, E. ewingii ehrlichiosis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Dogs, humans</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Granulocytes</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>White-tailed deer, dogs?</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Ehrlichia canis (including the Venezuelan human Ehrlichia strain)</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Rhipicephalus sanguineus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Venezuela, Costa Rica</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>CME, VHE</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Dogs, humans</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Monocytes</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Dogs</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Ehrlichia ruminantium</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Amblyomma species</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Caribbean, southern Africa</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Heartwater</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Domestic and wild ruminants</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Granulocytes, endothelial cells</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ruminants</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Ehrlichia muris subsp. muris</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Haemaphysalis flava, Ixodes persulcatus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Asia, Eastern Europe</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>E. muris ehrlichiosis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Small mammals, humans, dogs? Bear? Monkeys? Boar?</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Macrophages</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Rodents, sika deer</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Ehrlichia muris subsp. eauclairensis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes scapularis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Upper Midwestern U.S. (Minnesota, Wisconsin)</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>E. muris ehrlichiosis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Humans</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Macrophages? Endothelial cells?</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Rodents</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Ehrlichia species (IOE)</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes ovatus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Japan</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Not named</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Laboratory and wild mice and rodents</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Macrophages, Kupffer cells, endothelial cells</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Not known</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Neorickettsia</emphasis>
                  </phrase>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Neorickettsia sennetsu</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Unknown; possibly ingestion of fluke-infested fish</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Malaysia, Japan, other parts of Asia</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Sennetsu fever</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Humans</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Monocytes</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Fluke-infested fish? Snails?</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Neorickettsia risticii, Neorickettsia findlayensis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ingestion of fluke-infested insects, snails</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>North America</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Potomac horse fever</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Horses</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Monocytes, enterocytes; mast cells?</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Snails, aquatic insects?</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Neorickettsia helminthoeca</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ingestion of fluke-infested salmonid fish</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Northwest Pacific coast of U.S., Brazil?</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Salmon poisoning disease</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Dogs, bears?</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Monocytes, macrophages</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Snails, fluke-infested fish, Pacific giant salamander</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left"><emphasis>Genus and species incertae sedis</emphasis><superscript><emphasis><link linkend="ch0085s0000a0011">a</link></emphasis></superscript> <emphasis>or Candidatus status</emphasis></phrase>
                </entry>
                <entry/>
                <entry/>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>Aegyptianella spp.</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Amblyomma spp., Argas persicus</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Egypt, North America</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Aegyptianellosis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Birds, amphibians, reptiles</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Erythrocytes</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Not known</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>“Candidatus Neoehrlichia mikurensis”</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes ricinus, Ixodes ovatus, Ixodes persulcatus, Haemaphysalis spp.?</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Asia, Northern Europe</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Neoehrlichiosis</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Humans, rodents</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Endothelial cells, granulocytes</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Rodents</emphasis>
                  </phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">
                    <emphasis>“Candidatus Neoehrlichia lotoris”</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Ixodes spp.?</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>North America</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>No disease</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Raccoons</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Not known</emphasis>
                  </phrase>
                </entry>
                <entry><phrase role="left">
                    <emphasis>Raccoons</emphasis>
                  </phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0085s0000a0011"/><link linkend="ch0085s0000a0010">a</link></emphasis></superscript>Modified from <ulink url="ch0084#ch0084s0001">chapter 67</ulink> of the 9th edition of this <emphasis>Manual.</emphasis> Abbreviations: EGE, equine granulocytic ehrlichiosis (anaplasmosis); CGE, canine granulocytic ehrlichiosis; CME, canine monocytic ehrlichiosis; IOE, <emphasis>Ixodes ovatus Ehrlichia;</emphasis> VHE, Venezuelan human ehrlichiosis.</para>
        <para role="table-footnote"><superscript><emphasis>b</emphasis></superscript>Uncertain/undecided taxonomic classification.</para>
        <figure id="ch0085s0000f0002"><title><phrase role="figureLabel"><anchor id="ch0085s0000a0012"/><link linkend="ch0085s0000a0006">FIGURE 2</link></phrase> (A and B) Wright stains (magnification, ×1,000) of <emphasis>A. phagocytophilum</emphasis> (A) and <emphasis>E. chaffeensis</emphasis> (B) in peripheral blood leukocytes. Note that an <emphasis>E. chaffeensis</emphasis> morula (arrowhead) is present in a monocyte (B) and that an <emphasis>A. phagocytophilum</emphasis> morula (arrow) is present in a neutrophil (A). (C) Romanowsky (Leukostat) stain (magnification, ×1,000) of <emphasis>E. chaffeensis</emphasis> cultured in the canine histiocyte cell line DH82. Note the presence of basophilic, stippled, intracytoplasmic inclusions approximately 2 to 3 μm in diameter (arrows). The smaller intracytoplasmic granules may also be ehrlichial morulae. (D) Wright stain (magnification, × 1,000) of <emphasis>A. phagocytophilum</emphasis> from the blood of an infected patient cultured in the human promyelocytic cell line HL-60. Note the presence of multiple basophilic, stippled, intracytoplasmic inclusions (arrowheads) in an HL-60 cell.</title>
          
          <mediaobject>
            <imageobject>
              <imagedata fileref="Ch0085f05.jpg" width="100%" scalefit="1"/>
            </imageobject>
          </mediaobject>
        </figure>
      </sect2>
      <sect2 id="ch0085s0001s0003">
        <title>EPIDEMIOLOGY AND TRANSMISSION</title>
        <anchor id="ch0085s0001a0004"/>
        <anchor id="ch0085s0000a0013"/>
        <para id="ch0085s0000p0008">Genera that make up the<emphasis>Anaplasmataceae</emphasis> can be classified by whether they are transmitted by ticks; <emphasis>Ehrlichia, Anaplasma</emphasis>, and “<emphasis>Candidatus</emphasis> Neoehrlichia” spp. are tick-borne pathogens, while <emphasis>Neorickettsia sennetsu</emphasis> and <emphasis>Wolbachia</emphasis> spp. are not. Rather than tick transmission, <emphasis>Neorickettsia sennetsu</emphasis> is thought to be acquired by humans following ingestion of fish infested with infected digenean trematodes (flukes), but some pathogenic veterinary <emphasis>Neorickettsia</emphasis> species can be acquired by consumption of aquatic insects that harbor trematode metacercariae (<link linkend="ch0085s0000li0021">21</link>, <link linkend="ch0085s0000li0031">31</link>). <emphasis>Wolbachia</emphasis> spp. are not currently known to cause human disease but are important endosymbionts of a broad range of arthropods, helminths, and crustaceans, including disease-causing filaria (<link linkend="ch0085s0000li0022">22</link>, <link linkend="ch0085s0000li0023">23</link>). They are found in all stages of filarial nematodes and are transmitted vertically after infection of the helminth ovary (<link linkend="ch0085s0000li0007">7</link>, <link linkend="ch0085s0000li0032">32</link>).</para>
        <anchor id="ch0085s0000a0014"/>
        <beginpage pagenum="1296"/>
        <anchor id="ch0085s0000a0015"/>
        <beginpage pagenum="1297"/>
        <para id="ch0085s0000p0009">Ticks become infected with<emphasis>Ehrlichia, Anaplasma</emphasis>, and “<emphasis>Ca.</emphasis> Neoehrlichia” species when larvae or nymphs ingest these bacteria while feeding on an infected animal. Transovarial transmission has not been described, but transstadial transmission is well recognized. Newly infected ticks molt into the next life cycle stage after feeding and can then transmit the bacteria to a new mammalian host. Both ticks and nonhuman mammals serve as reservoirs (<link linkend="ch0085s0000li0033">33</link>, <link linkend="ch0085s0000li0034">34</link>). In contrast, humans are accidental, dead-end hosts. Therefore, maintenance of tick-borne infection in nature depends upon the presence of appropriate tick vectors and mammalian hosts in the local environment (<link linkend="ch0085s0000li0034">34</link>–<link linkend="ch0085s0000li0036">36</link>) (<link linkend="ch0085s0000a0009">Table 1</link>). The epidemiology of each tick-borne infection reflects the seasonal activities and geographic distribution of the associated vectors and hosts. In the United States, cases of ehrlichiosis and anaplasmosis can occur in any month, but most are reported during April through September, with peak reports in June and July, coinciding with the corresponding levels of the tick vector’s host-seeking and feeding activities (<link linkend="ch0085s0000li0037">37</link>–<link linkend="ch0085s0000li0040">40</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0085s0002">
      <title>Anaplasmosis (Human Granulocytic Anaplasmosis)</title>
      <anchor id="ch0085s0002a0001"/>
      <anchor id="ch0085s0000a0016"/>
      <para id="ch0085s0000p0010">Anaplasmosis (previously known as human granulocytic ehrlichiosis [HGE]) is the most widespread of the tick-transmitted human diseases due to members of the<emphasis>Anaplasmataceae.</emphasis> The causative agent was initially known as <emphasis>Rickettsia phagocytophila</emphasis> and later as <emphasis>Ehrlichia phagocytophila</emphasis>, before being renamed <emphasis>Anaplasma phagocytophilum</emphasis> based on phylogenetic studies (<link linkend="ch0085s0000li0001">1</link>). Most cases occur in the United States, but increasing numbers of cases are reported in Canada, Europe (primarily Scandinavia and Central Europe), and eastern regions of Asia (<link linkend="ch0085s0000li0016">16</link>, <link linkend="ch0085s0000li0041">41</link>–<link linkend="ch0085s0000li0044">44</link>). <emphasis>A. phagocytophilum</emphasis> is vectored by ticks in the <emphasis>Ixodes persulcatus</emphasis> complex, including <emphasis>Ixodes scapularis</emphasis> (the black-legged tick or deer tick) in the northeastern and upper midwestern United States, <emphasis>I. pacificus</emphasis> (the pacific black-legged tick) in the northwestern United States, and <emphasis>I. ricinus</emphasis> (the castor bean tick) and <emphasis>I. persulcatus</emphasis> (the taiga tick) in Europe (<link linkend="ch0085s0000li0041">41</link>–<link linkend="ch0085s0000li0044">44</link>). <emphasis>Ixodes persulcatus</emphasis> is also the vector in Asia. Importantly, these ticks are also vectors for members of the <emphasis>Borrelia burgdorferi sensu lato</emphasis> complex (causative agents of Lyme borreliosis) and several viral, bacterial, and parasitic pathogens, and more than one of these pathogens can be transmitted by the tick to its host during feeding (<link linkend="ch0085s0000li0039">39</link>, <link linkend="ch0085s0000li0045">45</link>). Other ticks may also serve as vectors for <emphasis>A. phagocytophilum</emphasis>; for example, <emphasis>Haemaphysalis concinna</emphasis> has been implicated as a vector in eastern Asia (<link linkend="ch0085s0000li0046">46</link>). Less common means of transmission to humans are blood product transfusion (<link linkend="ch0085s0000li0047">47</link>, <link linkend="ch0085s0000li0048">48</link>), solid organ transplantation (<link linkend="ch0085s0000li0048">48</link>), and perinatal transmission (<link linkend="ch0085s0000li0049">49</link>).</para>
      <para id="ch0085s0000p0011">Human anaplasmosis was first recognized in 1990 in a patient residing in Wisconsin (<link linkend="ch0085s0000li0012">12</link>) but did not become a nationally notifiable disease in the United States until 1999, and the number of reported cases has mostly increased each year since then (<link linkend="ch0085s0000li0039">39</link>). In Europe, the first recognized case of human anaplasmosis was in 1997 in a patient residing in Slovenia (<link linkend="ch0085s0000li0050">50</link>). Prior to these first cases, <emphasis>A. phagocytophilum</emphasis> had been known to infect domestic ruminants in Europe and horses in the United States since the mid-20th century (<link linkend="ch0085s0000li0016">16</link>). There were 5,655 cases of confirmed or probable anaplasmosis reported to the U.S. Centers for Disease Control and Prevention (CDC) in 2019 (<link linkend="ch0085s0000li0037">37</link>, <link linkend="ch0085s0000li0039">39</link>, <link linkend="ch0085s0000li0045">45</link>). These case counts are slightly above those reported for the spotted fever group rickettsioses (including Rocky Mountain spotted fever) in the United States in 2019 (<emphasis>n</emphasis> = 5,207), making anaplasmosis the second most common tick-borne disease in the United States, after Lyme disease (<link linkend="ch0085s0000li0051">51</link>). Cases were reported from 37 states and from New York City, with most cases being from states in the Upper Midwest and northeastern seaboard. New York, Massachusetts, Maine, Vermont, Minnesota, Wisconsin, New Hampshire, and Connecticut accounted for almost 9 of 10 reported cases of anaplasmosis in 2019, with Vermont having the highest incidence rate per million persons at risk (857.4) (<link linkend="ch0085s0000li0039">39</link>). Males and individuals over the age of 40 have the highest frequency of reported disease. Of note, anaplasmosis has a bimodal seasonality; symptom onset is primarily during the spring and summer months (May through August) corresponding to the peak time of the nymphs’ host-seeking behavior, but there is a smaller peak of cases in October corresponding to host seeking by adult ticks (<link linkend="ch0085s0000li0037">37</link>, <link linkend="ch0085s0000li0039">39</link>, <link linkend="ch0085s0000li0045">45</link>).</para>
      <anchor id="ch0085s0000a0017"/>
      <beginpage pagenum="1298"/>
      <para id="ch0085s0000p0012">While passive surveillance via national reporting provides important information for estimating disease risk in different geographic regions of the United States, it likely underestimates the true prevalence of anaplasmosis, since it relies on voluntary reporting by health care systems and may not capture cases of subclinical or mild disease. Studies using active surveillance methods highlight this disparity. For example, research conducted using sera from residents and blood donors residing in regions of the United States where disease is endemic has reported seroprevalence rates of 0.5% (Wisconsin blood donors), 3.5% (Connecticut blood donors), 5.1% (children living in Westchester County, NY, being tested for an endocrinologic disorder), 11.3% (Westchester County, NY, blood donors), and 14.9% (Wisconsin residents) (<link linkend="ch0085s0000li0052">52</link>–<link linkend="ch0085s0000li0054">54</link>). Of note, none of the 14.9% of Wisconsin residents with positive serology results had a history suggestive of anaplasmosis, indicating that their infections were mild or subclinical, and there was no association between the test result and history of tick bite (<link linkend="ch0085s0000li0052">52</link>). Other studies have shown higher seropositivity rates in patients with evidence of tick bites, with 35.6% of adults living in Westchester County and 23.3% of specimens submitted to a large reference laboratory in Winnipeg, Manitoba, Canada, for Lyme disease testing being positive for antibodies reacting with <emphasis>A. phagocytophilum</emphasis> (<link linkend="ch0085s0000li0053">53</link>, <link linkend="ch0085s0000li0055">55</link>). In Europe, reported seroprevalence rates in blood donors range from 0 to 2.9%, with higher rates (1.5 to 21%) in individuals reporting tick exposure (<link linkend="ch0085s0000li0042">42</link>).</para>
      <para id="ch0085s0000p0013"><emphasis>A. phagocytophilum</emphasis> DNA has been detected from a wide range of mammals and birds, and this organism is a known pathogen of humans, dogs, horses, and several wild and domestic ruminants (<link linkend="ch0085s0000li0016">16</link>, <link linkend="ch0085s0000li0056">56</link>). Some of these animals have been demonstrated to serve as competent reservoir hosts. The primary reservoir hosts of <emphasis>A. phagocytophilum</emphasis> are small mammals such as white-footed mice (<emphasis>Peromyscus leucopus</emphasis>), chipmunks (<emphasis>Tamias striatus</emphasis>), voles (<emphasis>Clethrionomys gapperi</emphasis>), and other wild rodents (<link linkend="ch0085s0000li0016">16</link>). Although white-tailed deer can be persistently infected by <emphasis>A. phagocytophilum</emphasis>, the strains (AP variant 1) that naturally infect deer are not infectious for small mammals, have not been identified in humans, and likely represent nonpathogenic variants (<link linkend="ch0085s0000li0057">57</link>). Persistent or prolonged infection in animal reservoir hosts is essential for maintenance of zoonoses like anaplasmosis. Mice infected with <emphasis>A. phagocytophilum</emphasis> can remain infected for months, and this contributes to its transmission to different stages of developing <emphasis>I. scapularis</emphasis> ticks (<link linkend="ch0085s0000li0058">58</link>). In Europe, red deer, sheep, cattle, and goats are persistently infected and serve as reservoirs of <emphasis>A. phagocytophilum</emphasis>.</para>
      <para id="ch0085s0000p0014">Other species of<emphasis>Anaplasma</emphasis> have been described to infect humans; <emphasis>Anaplasma capra</emphasis> was detected among 28 patients in China, and a single patient was infected with <emphasis>Anaplasma ovis</emphasis> in Cyprus (<link linkend="ch0085s0000li0059">59</link>, <link linkend="ch0085s0000li0060">60</link>).</para>
    </sect1>
    <sect1 id="ch0085s0003">
      <title>Human Ehrlichiosis</title>
      <anchor id="ch0085s0003a0001"/>
      <anchor id="ch0085s0000a0018"/>
      <para id="ch0085s0000p0015">Most cases of human ehrlichiosis occur in the United States, where the three primary causative agents are<emphasis>E. chaffeensis, E. ewingii</emphasis>, and <emphasis>E. muris</emphasis> subsp. <emphasis>eauclairensis.</emphasis> Other <emphasis>Ehrlichia</emphasis> species, including the Panola Mountain <emphasis>Ehrlichia</emphasis> species and <emphasis>E. canis</emphasis>, have also been reported to cause human disease in the United States and other regions of the world (<link linkend="ch0085s0000li0061">61</link>, <link linkend="ch0085s0000li0062">62</link>); significant human pathogens are outlined in <link linkend="ch0085s0000a0009">Table 1</link>. Although infections have previously been named based on the primary cell type infected (e.g., human monocytic ehrlichiosis [HME]), the preference is now to designate the type of disease based on the causative agent (e.g., <emphasis>E. chaffeensis</emphasis> ehrlichiosis) in order to avoid confusion. <emphasis>E. chaffeensis</emphasis> ehrlichiosis is the most common form of ehrlichiosis in the United States (<link linkend="ch0085s0000li0038">38</link>, <link linkend="ch0085s0000li0045">45</link>).</para>
      <para id="ch0085s0000p0016">Ehrlichiosis is transmitted almost exclusively through the bite of infected ticks.<emphasis>E. chaffeensis</emphasis> ehrlichiosis is transmitted to humans by <emphasis>Amblyomma americanum</emphasis> (the lone star tick), an aggressive hard-bodied tick that indiscriminately feeds on a wide range of hosts, including humans (<link linkend="ch0085s0000li0045">45</link>). This tick also transmits <emphasis>E. ewingii. A. americanum</emphasis> is one of the most commonly encountered ticks in the southeastern United States and has a range that extends into New England and the Upper Midwest. Its range overlaps that of <emphasis>I. scapularis</emphasis> in many areas, and thus, patients with tick exposure can be at risk from pathogens transmitted by both tick species. In comparison to <emphasis>E. chaffeensis</emphasis> and <emphasis>E. ewingii, E. muris</emphasis> subsp. <emphasis>eauclairensis</emphasis> is transmitted to humans by <emphasis>I. scapularis</emphasis> (<link linkend="ch0085s0000li0063">63</link>). Less commonly, human ehrlichiosis can be transmitted through solid organ transplantation and blood transfusion (<link linkend="ch0085s0000li0048">48</link>, <link linkend="ch0085s0000li0064">64</link>–<link linkend="ch0085s0000li0066">66</link>).</para>
      <para id="ch0085s0000p0017">The first cases of<emphasis>E. chaffeensis, E. ewingii</emphasis>, and <emphasis>E. muris</emphasis> subsp. <emphasis>eauclairensis</emphasis> ehrlichiosis were documented in 1991, 1999, and 2011, respectively (<link linkend="ch0085s0000li0063">63</link>, <link linkend="ch0085s0000li0067">67</link>, <link linkend="ch0085s0000li0068">68</link>). <emphasis>E. muris</emphasis> subsp. <emphasis>eauclairensis</emphasis> was initially referred to as the <emphasis>Ehrlichia muris-</emphasis>like agent due to its genetic similarities to <emphasis>Ehrlichia muris</emphasis> found in Eurasia (<link linkend="ch0085s0000li0069">69</link>). While ehrlichiosis has been a nationally notifiable disease in the United States since 1999, it was only in 2008 that the case definition was refined to differentiate infection with <emphasis>E. chaffeensis, E. ewingii</emphasis>, and <emphasis>A. phagocytophilum</emphasis> (previously classified as an <emphasis>Ehrlichia</emphasis> species) (<link linkend="ch0085s0000li0038">38</link>, <link linkend="ch0085s0000li0040">40</link>).</para>
      <para id="ch0085s0000p0018">According to data reported to the CDC, 4,613 cases of<emphasis>E. chaffeensis</emphasis> infection and 55 cases of <emphasis>E. ewingii</emphasis> infection occurred during 2008 to 2012, representing incidence rates of 3.2 and 0.04 cases per million person-years, respectively (<link linkend="ch0085s0000li0038">38</link>). There were 2,093 cases reported in 2019, which represents a 10-fold increase in ehrlichiosis cases since 2000 (<link linkend="ch0085s0000li0040">40</link>). Cases of <emphasis>E. chaffeensis</emphasis> ehrlichiosis are most frequently reported from the south-central and southeastern United States, extending from Texas to the East Coast (<link linkend="ch0085s0000li0040">40</link>). Missouri, Arkansas, North Carolina, and New York accounted for nearly 50% of reported cases in 2019. The incidence rate increased with age, with the highest rate occurring among individuals 65 to 69 years of age (<link linkend="ch0085s0000li0040">40</link>). Males accounted for the majority of cases.</para>
      <para id="ch0085s0000p0019">From 2008 to 2012, there were only 55 reported cases of<emphasis>E. ewingii</emphasis> ehrlichiosis. Cases were reported from 12 states, with 69% reported from Missouri, Delaware, and Tennessee (<link linkend="ch0085s0000li0038">38</link>). Incidence rates increased with age, with individuals 65 years and older having the highest rate compared to other members of the population. Males accounted for 51% of cases (<link linkend="ch0085s0000li0038">38</link>). There have now been 261 cases of <emphasis>E. ewingii</emphasis> ehrlichiosis reported from 2008 to 2019 (<link linkend="ch0085s0000li0040">40</link>).</para>
      <para id="ch0085s0000p0020">In contrast to anaplasmosis, human ehrlichiosis due to<emphasis>E. chaffeensis</emphasis> and <emphasis>E. ewingii</emphasis> does not have a bimodal distribution. Most cases occur during May through August, with peak occurrences in June (<emphasis>E. chaffeensis</emphasis> ehrlichiosis) and July (<emphasis>E. ewingii</emphasis> ehrlichiosis) (<link linkend="ch0085s0000li0038">38</link>).</para>
      <para id="ch0085s0000p0021">To date,<emphasis>E. muris</emphasis> subsp. <emphasis>eauclairensis</emphasis> has been detected only in patients exposed to ticks in Minnesota and Wisconsin (<link linkend="ch0085s0000li0070">70</link>) and has not been detected in patient specimens collected outside Minnesota and Wisconsin (<link linkend="ch0085s0000li0063">63</link>, <link linkend="ch0085s0000li0070">70</link>, <link linkend="ch0085s0000li0071">71</link>). While most positive ticks have been from Minnesota and Wisconsin, <emphasis>E. muris</emphasis> subsp. <emphasis>eauclairensis</emphasis> was recently detected in an <emphasis>I. scapularis</emphasis> tick collected in Menominee County, Michigan (<link linkend="ch0085s0000li0072">72</link>), and this agent was also detected in an <emphasis>Ixodes muris</emphasis> tick collected in 2011 in Manitoba (R. Lindsay and A. Dibernardo, personal communication). Furthermore, a distinct clade of <emphasis>E. muris</emphasis> has been detected in <emphasis>Ixodes cookei</emphasis> ticks collected in Maine and New York states (<link linkend="ch0085s0000li0073">73</link>). The public health significance of this finding is unclear.</para>
      <anchor id="ch0085s0000a0019"/>
      <beginpage pagenum="1299"/>
      <para id="ch0085s0000p0022">Sixty-nine cases of<emphasis>E. muris</emphasis> subsp. <emphasis>eauclairensis</emphasis> ehrlichiosis have been reported in a case series spanning 2007 to 2013 (<link linkend="ch0085s0000li0070">70</link>), and additional human cases continue to be detected in patients with exposure to ticks in the Upper Midwest (<link linkend="ch0085s0000li0074">74</link>).</para>
      <para id="ch0085s0000p0023">A significant limiting factor for national ehrlichiosis reporting in the United States is that case definitions are based largely on serologic testing, which exhibits significant cross-reactivity among<emphasis>Ehrlichia</emphasis> species due to antigenic similarity. A high level of serologic cross-reactivity with <emphasis>A. phagocytophilum</emphasis> is also observed. Thus, serologic test results must be interpreted in the context of clinical and epidemiologic features. Most reports of <emphasis>E. chaffeensis</emphasis> human and canine infection from the Upper Midwest, for example, likely reflect <emphasis>E. muris</emphasis> subsp. <emphasis>eauclairensis</emphasis> infection given that <emphasis>I. scapularis</emphasis> is the primary tick vector of human diseases in this state (<link linkend="ch0085s0000li0038">38</link>, <link linkend="ch0085s0000li0056">56</link>, <link linkend="ch0085s0000li0075">75</link>). Also, cases of <emphasis>E. ewingii</emphasis> ehrlichiosis must be PCR positive to meet the case definition, and cases tested only by serologic methods may be incorrectly classified as <emphasis>E. chaffeensis</emphasis> ehrlichiosis.</para>
      <para id="ch0085s0000p0024">As with anaplasmosis, passive surveillance methods could significantly underestimate the true incidence of human ehrlichiosis (<link linkend="ch0085s0000li0076">76</link>). Prospective evaluation of heavily exposed cohorts shows that approximately 75% of seroconversions are subclinical, and thus, many infected individuals might not undergo testing to evaluate for ehrlichiosis (<link linkend="ch0085s0000li0077">77</link>). The diagnosis could also be missed when appropriate testing is not ordered. A retrospective seroprevalence study testing residual sera from children (ages 1 to 17 years) submitted in 1999 for any reason to seven academic pediatric medical centers in the southeastern and south-central United States detected antibodies reacting with <emphasis>E. chaffeensis</emphasis> (titers of 80 or higher) in 13% (<link linkend="ch0085s0000li0078">78</link>). The positivity rate ranged from 2% (Louisville, KY) to 22% (Winston-Salem, NC).</para>
      <para id="ch0085s0000p0025">White-tailed deer (<emphasis>Odocoileus virginianus</emphasis>) are the primary reservoirs for <emphasis>E. chaffeensis</emphasis> and <emphasis>E. ewingii</emphasis>, with domestic dogs also serving as reservoirs (<link linkend="ch0085s0000li0036">36</link>, <link linkend="ch0085s0000li0079">79</link>, <link linkend="ch0085s0000li0080">80</link>). Birds and mammals that host <emphasis>Amblyomma</emphasis> ticks could also serve as minor reservoirs (<link linkend="ch0085s0000li0081">81</link>). In addition to their role as a reservoir, domestic dogs also serve as transport hosts by bringing infected <emphasis>A. americanum</emphasis> ticks into close proximity to human households (<link linkend="ch0085s0000li0082">82</link>). The full spectrum of reservoirs for <emphasis>E. muris</emphasis> subsp. <emphasis>eauclairensis</emphasis> is not yet known, but white-footed mice are known to be an important reservoir (<link linkend="ch0085s0000li0083">83</link>, <link linkend="ch0085s0000li0084">84</link>). This organism was not detected in a convenience sampling of blood from 181 white-tailed deer killed in Camp Ripley, Minnesota, during the 2010 archery season (14 September to 31 December) (<link linkend="ch0085s0000li0084">84</link>).</para>
    </sect1>
    <sect1 id="ch0085s0004">
      <title>Neorickettsiosis (Sennetsu Fever)</title>
      <anchor id="ch0085s0004a0001"/>
      <anchor id="ch0085s0000a0020"/>
      <para id="ch0085s0000p0026">Named after the Japanese term for glandular fever,<emphasis>Neorickettsia sennetsu</emphasis> was first identified from a Japanese patient with suspected infectious mononucleosis in 1953 (<link linkend="ch0085s0000li0085">85</link>) and has since been reported from patients in the Southeast Asian countries of Malaysia, Thailand, and Laos (<link linkend="ch0085s0000li0031">31</link>, <link linkend="ch0085s0000li0086">86</link>). <emphasis>Neorickettsia</emphasis> species are thought to be transmitted to vertebrate hosts through ingestion of infected trematodes in undercooked fish and aquatic insects (<link linkend="ch0085s0000li0008">8</link>). While ingestion of the gray mullet, <emphasis>Mugil cephalus</emphasis>, was implicated in the index case of human neorickettsiosis, and <emphasis>N. sennetsu</emphasis> DNA has been detected in the climbing perch, <emphasis>Anabas testudineus</emphasis>, the bacterium has yet to be detected in trematodes (<link linkend="ch0085s0000li0008">8</link>, <link linkend="ch0085s0000li0031">31</link>, <link linkend="ch0085s0000li0087">87</link>). This is in contrast to the related organisms <emphasis>Neorickettsia helminthoeca</emphasis> (agent of salmon poisoning disease of canids) and <emphasis>N. risticii</emphasis> (agent of Potomac horse fever), which have been found in all stages of nematode hosts (<link linkend="ch0085s0000li0008">8</link>), although the entire genome of a <emphasis>Neorickettsia</emphasis> sp. highly syntenic with <emphasis>N. sennetsu</emphasis> and <emphasis>N. risticii</emphasis> was identified in <emphasis>Fasciola hepatica</emphasis> from Oregon and Uruguay (<link linkend="ch0085s0000li0087">87</link>).</para>
      <para id="ch0085s0000p0027">Human infection is rare, with fewer than 100 cases reported worldwide as of 2015 (<link linkend="ch0085s0000li0088">88</link>). However, antibodies reacting with <emphasis>N. sennetsu</emphasis> have been reported in a relatively high percentage (17%) of adults in Laos and 0.2 to 4% of febrile patients in Thailand, suggesting that both infections may be underrecognized (<link linkend="ch0085s0000li0031">31</link>, <link linkend="ch0085s0000li0086">86</link>).</para>
    </sect1>
    <sect1 id="ch0085s0005">
      <title>Neoehrlichiosis</title>
      <anchor id="ch0085s0005a0001"/>
      <anchor id="ch0085s0000a0021"/>
      <para id="ch0085s0000p0028">Neoehrlichiosis is an emerging tick-borne human infection in Europe and Asia caused by “<emphasis>Ca.</emphasis> Neoehrlichia mikurensis” (<link linkend="ch0085s0000li0089">89</link>–<link linkend="ch0085s0000li0091">91</link>). The first reported human case was in a Swedish man with chronic lymphocytic leukemia in 2010, more than a decade after the organism was recognized in Dutch <emphasis>I. ricinus</emphasis> ticks (<link linkend="ch0085s0000li0006">6</link>, <link linkend="ch0085s0000li0089">89</link>). “<emphasis>Ca.</emphasis> Neoehrlichia mikurensis” has also been detected in <emphasis>I. persulcatus</emphasis> and other ticks (<link linkend="ch0085s0000li0089">89</link>).</para>
      <para id="ch0085s0000p0029">Cases have now been reported involving more than 100 patients in Europe and China (<link linkend="ch0085s0000li0091">91</link>). The reservoirs for “<emphasis>Ca.</emphasis> Neoehrlichia mikurensis” are small mammals, including field mice and voles, in both Europe and Asia (<link linkend="ch0085s0000li0089">89</link>, <link linkend="ch0085s0000li0090">90</link>).</para>
      <sect2 id="ch0085s0005s0001">
        <title>CLINICAL SIGNIFICANCE</title>
        <anchor id="ch0085s0005a0002"/>
        <anchor id="ch0085s0000a0022"/>
      </sect2>
    </sect1>
    <sect1 id="ch0085s0006">
      <title>Human Granulocytic Anaplasmosis</title>
      <anchor id="ch0085s0006a0001"/>
      <anchor id="ch0085s0000a0023"/>
      <para id="ch0085s0000p0030">Anaplasmosis most commonly presents as a nonspecific acute febrile illness following a 5- to 11-day incubation period after a bite from an infected tick. The full clinical spectrum ranges from subclinical or mildly symptomatic illness, to severe, life-threatening disease, and there is a direct correlation between disease severity and patient age and/or presence of comorbidities (<link linkend="ch0085s0000li0037">37</link>). Symptomatic patients most commonly complain of fever (up to 100%), malaise (97%), headache (82%), myalgias (76%), and arthralgia (56%) (<link linkend="ch0085s0000li0041">41</link>). Gastrointestinal, respiratory, musculoskeletal, and central nervous system involvement occurs in fewer than half of patients. Rash has been observed in only 6% of patients and in all cases could be attributable to concurrent Lyme disease with erythema migrans (<link linkend="ch0085s0000li0041">41</link>). Meningoencephalitis is rarely reported (0.9% of cases) in anaplasmosis (<link linkend="ch0085s0000li0037">37</link>); however, other reported neurologic sequelae include facial diplegia, brachial plexopathy, and demyelinating polyneuropathy (<link linkend="ch0085s0000li0092">92</link>). Additional manifestations of severe disease include myocarditis, hepatitis, interstitial pneumonitis, hemophagocytic lymphohistiocytosis syndrome, and adult respiratory distress syndrome (ARDS) (<link linkend="ch0085s0000li0093">93</link>).</para>
      <para id="ch0085s0000p0031">The most common laboratory findings are increased serum transaminase activity (83%), thrombocytopenia (75%), and leukopenia (55%) with lymphopenia. Lymphocytosis with atypical lymphocytes can occur after the first week of infection (<link linkend="ch0085s0000li0094">94</link>, <link linkend="ch0085s0000li0095">95</link>). Anemia is less common, being reported in only 28% (<link linkend="ch0085s0000li0041">41</link>). Elevated levels of C-reactive protein occur in 96 to 100% and can be helpful in differentiating this disease from viral infections (<link linkend="ch0085s0000li0096">96</link>, <link linkend="ch0085s0000li0097">97</link>). Cerebral spinal fluid analysis is usually unremarkable, even in patients with suspected central nervous system manifestations (<link linkend="ch0085s0000li0098">98</link>).</para>
      <para id="ch0085s0000p0032">Data from cases occurring in the United States during 2008 to 2012 showed that 1,827 of 5,937 patients (31%) for which data were available had disease severe enough to warrant hospitalization (<link linkend="ch0085s0000li0037">37</link>). Among 2,825 cases with available data, 0.3% to 3% involved life-threatening complications such as renal failure, ARDS, meningitis or encephalitis, pneumonia, disseminated intravascular coagulopathy (DIC), and sepsis (<link linkend="ch0085s0000li0037">37</link>). Another case analysis reported life-threatening complications in 7% of identified patients (<link linkend="ch0085s0000li0099">99</link>). Reported case fatality rates vary. A subset of 16 patients from one region of China had significantly greater disease severity (including multiorgan dysfunction, gastrointestinal, renal, and hemorrhagic manifestations, and worse laboratory features) and a case fatality rate of 16%, whereas the case fatality rate was 2.6% among 46 other patients with anaplasmosis in Shandong Province and is 0.3% in the United States (<link linkend="ch0085s0000li0037">37</link>, <link linkend="ch0085s0000li0100">100</link>). There is some evidence that the cases in China reflect greater severity owing to concurrent infection by a tick-borne bunyavirus (<link linkend="ch0085s0000li0101">101</link>). In the United States, the highest case fatality rates have been observed in patients aged 70 or older (<link linkend="ch0085s0000li0037">37</link>).</para>
      <anchor id="ch0085s0000a0024"/>
      <beginpage pagenum="1300"/>
    </sect1>
    <sect1 id="ch0085s0007">
      <title>Ehrlichia chaffeensis Ehrlichiosis</title>
      <anchor id="ch0085s0007a0001"/>
      <anchor id="ch0085s0000a0025"/>
      <para id="ch0085s0000p0033">As with anaplasmosis, the spectrum of clinical presentations of<emphasis>E. chaffeensis</emphasis> ehrlichiosis ranges from subclinical infection to life-threatening disease (<link linkend="ch0085s0000li0099">99</link>). The median incubation period for HME is 9 days. Patients most commonly present with fever (97%), malaise (82%), headache (80%), myalgia (57%), and nausea (64%), without localizing physical findings (<link linkend="ch0085s0000li0099">99</link>). Other gastrointestinal (vomiting and diarrhea), respiratory (cough), and osteoarticular (joint pain) symptoms are present in less than 50% of patients (<link linkend="ch0085s0000li0099">99</link>). In comparison to anaplasmosis, petechial, macular, and maculopapular rashes occur with varied distribution and onset (<link linkend="ch0085s0000li0102">102</link>) and are most frequent in children (57% of cases) but occur in &lt;30% of adults (<link linkend="ch0085s0000li0040">40</link>, <link linkend="ch0085s0000li0103">103</link>). Central nervous system involvement is also well described, with stiff neck and confusion seen in 3% and 19% of cases, respectively (<link linkend="ch0085s0000li0099">99</link>, <link linkend="ch0085s0000li0104">104</link>). Patients with <emphasis>E. chaffeensis</emphasis> can also develop hemophagocytic lymphohistiocytosis syndrome (<link linkend="ch0085s0000li0105">105</link>, <link linkend="ch0085s0000li0106">106</link>).</para>
      <para id="ch0085s0000p0034">Abnormal laboratory parameters occur in at least 86% of patients and include increased serum transaminase levels (83%), thrombocytopenia (71%), and leukopenia (62%) with lymphopenia and/or neutropenia (<link linkend="ch0085s0000li0099">99</link>).</para>
      <para id="ch0085s0000p0035">Of<emphasis>E. chaffeensis</emphasis> ehrlichiosis cases occurring in the United States during 2008 to 2012, 57% were severe enough to warrant hospitalization, with 11% having life-threatening complications such as renal failure, ARDS, meningitis or encephalitis, pneumonia, DIC, and sepsis (<link linkend="ch0085s0000li0037">37</link>). Corresponding case fatality rates were fortunately low (1%). Other reports describe severe complications occurring in 9 to 17% of patients (<link linkend="ch0085s0000li0099">99</link>). Fulminant infections are more common in patients immunocompromised by HIV, high-dose corticosteroids, medications related to organ transplantation or specific immune suppression (e.g., rituximab), and diabetes (<link linkend="ch0085s0000li0038">38</link>, <link linkend="ch0085s0000li0107">107</link>–<link linkend="ch0085s0000li0110">110</link>). Of the cases reported in the United States during 2008 to 2012, 14% were in patients with an immunocompromising condition (<link linkend="ch0085s0000li0038">38</link>). The case fatality rate in the latter group was 0.7 to 1%, with the highest rates observed in children &lt;5 years of age and adults ≥70 years of age (<link linkend="ch0085s0000li0038">38</link>). Previously reported risk factors for death are male sex, advanced age, immunosuppression, delayed diagnosis, and lack of early treatment (<link linkend="ch0085s0000li0111">111</link>, <link linkend="ch0085s0000li0112">112</link>).</para>
    </sect1>
    <sect1 id="ch0085s0008">
      <title>Ehrlichia ewingii Ehrlichiosis</title>
      <anchor id="ch0085s0008a0001"/>
      <anchor id="ch0085s0000a0026"/>
      <para id="ch0085s0000p0036">Symptoms of<emphasis>E. ewingii</emphasis> ehrlichiosis are similar to those of <emphasis>E. chaffeensis</emphasis> ehrlichiosis and include fever, headache, myalgia, and malaise (<link linkend="ch0085s0000li0045">45</link>). Thrombocytopenia, leukopenia, and increased hepatic transaminase levels are common laboratory findings. Of the 52 cases occurring in the United States during 2008 to 2012 for which data were available, 40 (77%) patients had disease severe enough to warrant hospitalization (<link linkend="ch0085s0000li0038">38</link>). There were no reported fatalities. Data regarding immune status were available for 38 patients, of which 10 (26%) had an immunocompromising condition (<link linkend="ch0085s0000li0038">38</link>). This differs from earlier reports of <emphasis>E. ewingii</emphasis> ehrlichiosis that primarily involved immunocompromised patients.</para>
    </sect1>
    <sect1 id="ch0085s0009">
      <title>Ehrlichia muris subsp. eauclairensis</title>
      <anchor id="ch0085s0009a0001"/>
      <anchor id="ch0085s0000a0027"/>
      <para id="ch0085s0000p0037">From the limited data available, the clinical features of infection with<emphasis>Ehrlichia muris</emphasis> subsp. <emphasis>eauclairensis</emphasis> seem similar to those of other ehrlichioses, with fever, malaise, headache, and myalgia being the predominant reported symptoms (seen in 89%, 76%, 67%, and 60% of patients, respectively) (<link linkend="ch0085s0000li0070">70</link>). The most commonly observed laboratory values are elevated liver transaminases (78%), thrombocytopenia (67%), lymphopenia (53%), leukopenia (39%), and anemia (36%). No fatalities have been reported to date.</para>
    </sect1>
    <sect1 id="ch0085s0010">
      <title>Neorickettsia sennetsu</title>
      <anchor id="ch0085s0010a0001"/>
      <anchor id="ch0085s0000a0028"/>
      <para id="ch0085s0000p0038">Patients with neorickettsiosis develop a self-limited febrile illness with chills, headache, malaise, sore throat, anorexia, and generalized lymphadenopathy (<link linkend="ch0085s0000li0088">88</link>). Laboratory findings include early leukopenia and atypical lymphocytes in the peripheral blood during early convalescence. No fatalities or severe complications have been reported (<link linkend="ch0085s0000li0088">88</link>).</para>
    </sect1>
    <sect1 id="ch0085s0011">
      <title>“Candidatus Neoehrlichia mikurensis”</title>
      <anchor id="ch0085s0011a0001"/>
      <anchor id="ch0085s0000a0029"/>
      <para id="ch0085s0000p0039">There have been several reports of human neoehrlichiosis published to date (<link linkend="ch0085s0000li0089">89</link>, <link linkend="ch0085s0000li0091">91</link>). A 2015 review described 26 human cases, comprising 12 immunocompromised and 14 immunocompetent patients. These 12 cases involving immunocompromised patients were characterized by high fever (12/12), myalgias/arthralgias (8/12), vascular/thromboembolic events (6/12), weight loss (5/12), and rash (4/12) (<link linkend="ch0085s0000li0089">89</link>). Vascular events included deep vein thromboses, pulmonary embolism, transient ischemic attacks, and lower extremity edema (<link linkend="ch0085s0000li0089">89</link>). The 14 cases involving immunocompetent patients had a more variable clinical presentation, ranging from asymptomatic infection in five Polish patients to a fatal case in Germany. Additionally, seven immunocompetent hosts from China experienced fever (7/7), myalgia/arthralgia (4/7), and rash (1/7) (<link linkend="ch0085s0000li0089">89</link>). Host factors associated with severe illness in this review include advanced age and immunocompromised condition, including splenectomy (<link linkend="ch0085s0000li0089">89</link>). More recently, Höper and colleagues described a cohort of 40 Swedish patients diagnosed during 2009 to 2019 (<link linkend="ch0085s0000li0091">91</link>). The median patient age was 61 years, and there was an equal gender distribution. Of note, the majority (30/40 [75%]) of the patients were immunocompromised, and 60% experienced vascular complications, including 19 of the 30 immunocompromised patients (<link linkend="ch0085s0000li0091">91</link>). Most vascular events were venous in origin and included deep vein thrombosis (exclusively in immunocompromised patients), recurrent thrombophlebitis, and pulmonary embolism. Three of the 30 patients, all immunocompetent, experienced arteritis (<link linkend="ch0085s0000li0091">91</link>).</para>
    </sect1>
    <sect1 id="ch0085s0012">
      <title>Contributions of Wolbachia to Human Disease</title>
      <anchor id="ch0085s0012a0001"/>
      <anchor id="ch0085s0000a0030"/>
      <para id="ch0085s0000p0040">Although bloodstream infection by a<emphasis>Wolbachia</emphasis> species associated only with insects was reported in a febrile patient with non-Hodgkin lymphoma (<link linkend="ch0085s0000li0113">113</link>), <emphasis>Wolbachia</emphasis> spp. have not yet been shown to be directly pathogenic for humans or animals. However, evidence indicates a potential role for release of intracellular <emphasis>Wolbachia</emphasis> components from filarial helminths such as <emphasis>Brugia malayi, Onchocerca volvulus</emphasis>, and <emphasis>Wuchereria bancrofti</emphasis> while in their human hosts. In theory, these microbial components act as potentiators of inflammation and contribute to lymphatic obstruction associated with filarial infections (<link linkend="ch0085s0000li0114">114</link>). At a minimum, the endosymbionts are mutualists on which the helminths depend to enable survival from stage to stage.</para>
      <anchor id="ch0085s0000a0031"/>
      <beginpage pagenum="1301"/>
      <sect2 id="ch0085s0012s0001">
        <title>COLLECTION, TRANSPORT, AND STORAGE OF SPECIMENS</title>
        <anchor id="ch0085s0012a0002"/>
        <anchor id="ch0085s0000a0032"/>
        <para id="ch0085s0000p0041">The most commonly used methods for diagnosis of infection with members of the<emphasis>Anaplasmataceae</emphasis> are nucleic acid amplification testing (NAAT), serology, and microscopic examination of peripheral blood films for the presence of morulae (<link linkend="ch0085s0000li0045">45</link>, <link linkend="ch0085s0000li0115">115</link>). This section focuses on collection of specimens for detection of <emphasis>A. phagocytophilum</emphasis> and <emphasis>Ehrlichia</emphasis> species.</para>
        <para id="ch0085s0000p0042">For serologic confirmation of anaplasmosis and ehrlichiosis, testing of at least two serum specimens is recommended: one obtained during acute illness and a second during the convalescence period, 2 to 4 weeks later (<link linkend="ch0085s0000li0045">45</link>). Testing of a single serum sample, particularly if it was collected during the acute phase, may be of limited clinical utility, as antibodies are frequently undetectable or at low titers during this time, and regional high seroprevalence makes it difficult to differentiate between recent and past infection. Specimens should be collected in a specific transport device (e.g., clot tube or serum separator tube [SST]) and transported to the laboratory at room temperature within 2 h of collection (<link linkend="ch0085s0000li0116">116</link>). Most serologic testing for these pathogens is performed at reference laboratories, which require longer transport times. If referral testing is necessary, centrifuged SSTs or serum aliquoted from the clot tube should be sent refrigerated or frozen (<link linkend="ch0085s0000li0116">116</link>).</para>
        <para id="ch0085s0000p0043">EDTA-anticoagulated whole blood is the preferred specimen for NAATs and blood smears for detection of<emphasis>A. phagocytophilum</emphasis> and <emphasis>Ehrlichia</emphasis> spp., as these are intracellular pathogens infecting leukocytes. Therefore, serum and plasma should not be used for these methods. Whole blood should be obtained during the active phase of illness, ideally before the start of antibiotic therapy (<link linkend="ch0085s0000li0045">45</link>, <link linkend="ch0085s0000li0099">99</link>, <link linkend="ch0085s0000li0116">116</link>–<link linkend="ch0085s0000li0118">118</link>). Samples should be obtained by sterile venipuncture and tested promptly by NAAT or frozen at −20 to −80°C for future testing (<link linkend="ch0085s0000li0045">45</link>, <link linkend="ch0085s0000li0116">116</link>). For blood smears, acute-phase peripheral blood buffy coat smears may be employed to increase the number of leukocytes examined on the slide; these should be prepared within hours of obtaining the sample, since leukocytes degenerate rapidly (<link linkend="ch0085s0000li0045">45</link>, <link linkend="ch0085s0000li0098">98</link>). Once prepared, air-dried blood smears and cytocentrifuged cerebrospinal fluid (CSF) preparations are stable at room temperature for months or years.</para>
        <para id="ch0085s0000p0044">Whole blood is also the preferred specimen for culture of<emphasis>Ehrlichia</emphasis> and <emphasis>Anaplasma</emphasis> species, although culture is typically performed only at public health or research laboratories. Similar to NAAT, samples for culture should be obtained by sterile venipuncture and processed as soon as possible or maintained at 4°C during shipping/storage, without freezing. <emphasis>A. phagocytophilum</emphasis> is easier to culture than <emphasis>E. chaffeensis</emphasis> and can be grown from EDTA-anticoagulated blood stored for up to 18 days at 4°C (<link linkend="ch0085s0000li0119">119</link>). Following isolation, <emphasis>Ehrlichia</emphasis> spp. and <emphasis>A. phagocytophilum</emphasis> can be stored frozen within infected host cells at −80°C for months and in liquid nitrogen for longer intervals for maintained viability. Storage of infected cells is best accomplished when more than 50 to 90% of the host cells are infected, and it is achieved by suspension of at least 10<superscript>6</superscript> cells per ml in tissue culture medium that contains 5 to 10% dimethyl sulfoxide and 10 to 45% fetal bovine serum (<link linkend="ch0085s0000li0120">120</link>, <link linkend="ch0085s0000li0121">121</link>).</para>
      </sect2>
      <sect2 id="ch0085s0012s0002">
        <title>LABORATORY DIAGNOSIS</title>
        <anchor id="ch0085s0012a0003"/>
        <anchor id="ch0085s0000a0033"/>
        <para id="ch0085s0000p0045">Testing for<emphasis>A. phagocytophilum</emphasis> and/or <emphasis>Ehrlichia</emphasis> species may not be available at the local clinical laboratory, particularly in settings where these organisms are not endemic, but is generally available at reference and public health laboratories (<link linkend="ch0085s0000li0122">122</link>). It is important to note that infections can be rapidly fatal and the results of diagnostic assays are rarely available at the time of initial patient management. Therefore, therapeutic decisions, including empiric therapy, often need to be made before test results are available (<link linkend="ch0085s0000li0045">45</link>, <link linkend="ch0085s0000li0112">112</link>, <link linkend="ch0085s0000li0115">115</link>).</para>
        <para id="ch0085s0000p0046">The methods used for laboratory diagnosis of anaplasmosis and ehrlichiosis vary significantly in their performance characteristics, availability, and time required to obtain results. Serodiagnosis, molecular amplification, and blood smear examination are used most commonly. Culture is rarely employed in the clinical laboratory but may be offered by specialized reference or public health laboratories (<link linkend="ch0085s0000li0116">116</link>). The recommended diagnostic tests for <emphasis>A. phagocytophilum</emphasis> and <emphasis>E. chaffeensis</emphasis> are outlined in Table 2. Note that the sensitivity of each method varies by the time in the course of infection and that different tests may be preferred during early and late stages of infection (<link linkend="ch0085s0000li0045">45</link>, <link linkend="ch0085s0000li0115">115</link>, <link linkend="ch0085s0000li0123">123</link>). In general, NAAT and blood smear examination provide the highest sensitivity during the first week of illness, while serologic testing offers the highest sensitivity during convalescence (<link linkend="ch0085s0000li0010">10</link>, <link linkend="ch0085s0000li0045">45</link>, <link linkend="ch0085s0000li0123">123</link>). Testing for <emphasis>A. phagocytophilum</emphasis> and <emphasis>E. chaffeensis</emphasis> should be conducted in facilities using biosafety level 2 (BSL-2) practices with standard precautions.</para>
        <anchor id="ch0085s0000a0034"/>
        <beginpage pagenum="1302"/>
        <table id="ch0085s0000t0002"><title><emphasis role="strong"><phrase role="figureLabel"><link linkend="ch0085s0000a0005">TABLE 2</link></phrase></emphasis> Comparison of diagnostics modalities for infection with <emphasis>Ehrlichia chaffeensis</emphasis> and <emphasis>Anaplasma phagocytophilum</emphasis>, by time after onset of clinical illness<superscript><emphasis><anchor id="ch0085s0000a0035"/><link linkend="ch0085s0000a0038">a</link></emphasis></superscript>
</title>
          
          <tgroup cols="3">
            <tbody>
              <row>
                <entry><phrase role="center">Wks after onset and diagnostic test</phrase>
                </entry>
                <entry><phrase role="center">Sensitivity (%)</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="center">Ehrlichiosis (<emphasis>E. chaffeensis</emphasis>)</phrase>
                </entry>
                <entry><phrase role="center">Anaplasmosis</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">≥1</phrase>
                </entry>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><phrase role="left">Blood smear</phrase>
                </entry>
                <entry><phrase role="left">2–38</phrase>
                </entry>
                <entry><phrase role="center">25–75</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">PCR</phrase>
                </entry>
                <entry><phrase role="left">60–85</phrase>
                </entry>
                <entry><phrase role="center">67–90</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Culture</phrase>
                </entry>
                <entry><phrase role="left">Highly variable<superscript><emphasis><anchor id="ch0085s0000a0036"/><link linkend="ch0085s0000a0039">b</link></emphasis></superscript></phrase>
                </entry>
                <entry><phrase role="center">≥55<superscript><emphasis><anchor id="ch0085s0000a0037"/><link linkend="ch0085s0000a0040">c</link></emphasis></superscript></phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Serologic testing</phrase>
                </entry>
                <entry><phrase role="left">22–55</phrase>
                </entry>
                <entry><phrase role="center">24–44</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">1–2</phrase>
                </entry>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><phrase role="left">Blood smear</phrase>
                </entry>
                <entry><phrase role="left">Unknown</phrase>
                </entry>
                <entry><phrase role="center">63</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">PCR</phrase>
                </entry>
                <entry><phrase role="left">Unknown</phrase>
                </entry>
                <entry><phrase role="center">68</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Culture</phrase>
                </entry>
                <entry><phrase role="left">Unknown</phrase>
                </entry>
                <entry><phrase role="center">33</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">Serologic testing</phrase>
                </entry>
                <entry><phrase role="left">68</phrase>
                </entry>
                <entry><phrase role="center">91</phrase>
                </entry>
              </row>
              <row>
                <entry><phrase role="left">≥3</phrase>
                </entry>
                <entry/>
                <entry/>
              </row>
              <row>
                <entry><phrase role="left">Serologic testing</phrase>
                </entry>
                <entry><phrase role="left">≥90</phrase>
                </entry>
                <entry><phrase role="center">≥95</phrase>
                </entry>
              </row>
            </tbody>
          </tgroup>
        </table>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0085s0000a0038"/><link linkend="ch0085s0000a0035">a</link></emphasis></superscript>Modified with permission from reference <link linkend="ch0085s0000li0099">99</link>.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0085s0000a0039"/><link linkend="ch0085s0000a0036">b</link></emphasis></superscript>May require weeks of incubation.</para>
        <para role="table-footnote"><superscript><emphasis><anchor id="ch0085s0000a0040"/><link linkend="ch0085s0000a0037">c</link></emphasis></superscript>May require weeks of incubation; results are often positive within 2 weeks.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0085s0013">
      <title>Direct Examination</title>
      <anchor id="ch0085s0013a0001"/>
      <anchor id="ch0085s0000a0041"/>
      <sect2 id="ch0085s0013s0001">
        <title>Microscopy by Romanowsky Staining of Peripheral Blood</title>
        <anchor id="ch0085s0013a0002"/>
        <anchor id="ch0085s0000a0042"/>
        <para id="ch0085s0000p0047">Examination of Giemsa- or Wright-stained peripheral blood or buffy coat leukocytes for the presence of characteristic intracellular morulae within granulocytes is a highly valuable, albeit inconsistent, technique in the diagnosis of anaplasmosis (<link linkend="ch0085s0000li0045">45</link>, <link linkend="ch0085s0000li0099">99</link>), with reported sensitivities of 25% to 75% (<link linkend="ch0085s0000li0123">123</link>, <link linkend="ch0085s0000li0124">124</link>). Examination of monocytes is a significantly less sensitive method for detection of <emphasis>E. chaffeensis</emphasis> ehrlichiosis, with sensitivities ranging from 2 to 38% (<link linkend="ch0085s0000li0124">124</link>, <link linkend="ch0085s0000li0125">125</link>). With both pathogens, accurate detection of morulae is highly operator dependent and should be performed by skilled and experienced microscopists (<link linkend="ch0085s0000li0045">45</link>). Usually, 800 to 1,000 granulocytes or monocytes are examined under magnifications of ×500 to ×1,000 for the presence of morulae (<link linkend="ch0085s0000li0126">126</link>), although a study of anaplasmosis revealed that as few as 200 neutrophils was sufficient to detect positive smears (<link linkend="ch0085s0000li0127">127</link>). Since most patients presenting with positive smears have &lt;1% infected cells and usually have leukopenia, buffy coat preparations will yield more than peripheral smears. Morulae of <emphasis>E. chaffeensis</emphasis> are most commonly identified from immunocompromised individuals. The number of detectable infected leukocytes in peripheral blood correlates modestly with severity of infection (<link linkend="ch0085s0000li0094">94</link>, <link linkend="ch0085s0000li0128">128</link>, <link linkend="ch0085s0000li0129">129</link>); the reported percentage of cells infected with <emphasis>E. chaffeensis</emphasis> ranges from 0.2% to 10% and can reach 40% or higher with <emphasis>A. phagocytophilum</emphasis> (<link linkend="ch0085s0000li0128">128</link>).</para>
        <para id="ch0085s0000p0048">Morulae are small (1- to 3-μm diameter), round to oval cohesive clusters of small bacteria that stain basophilic to amphophilic with Romanowsky stains (<link linkend="ch0085s0000a0012">Fig. 2</link>). These clusters are present within vacuoles in the cytoplasm of granulocytes (anaplasmosis) or monocytes (<emphasis>E. chaffeensis</emphasis> ehrlichiosis) and have a stippled appearance owing to individual bacteria within the vacuole. Various structures such as leukocyte toxic granulations, phagocytosed bacteria and yeasts, Döhle bodies, nuclear fragments, Auer rods, and overlying platelets can have a similar appearance and must be differentiated from true morulae (<link linkend="ch0085s0000li0045">45</link>).</para>
      </sect2>
      <sect2 id="ch0085s0013s0002">
        <title>Immunochemistry for Antigen Detection</title>
        <anchor id="ch0085s0013a0003"/>
        <anchor id="ch0085s0000a0043"/>
        <para id="ch0085s0000p0049">Immunochemical methods can also be used to identify<emphasis>A. phagocytophilum</emphasis> and <emphasis>E. chaffeensis</emphasis> in cytological preparations (e.g., cytocentrifuged CSF) or within formalin-fixed, paraffin-embedded human tissue, including bone marrow, liver, and spleen, and may be of particular utility for confirming the diagnosis in specimens obtained at autopsy (<link linkend="ch0085s0000li0124">124</link>, <link linkend="ch0085s0000li0130">130</link>, <link linkend="ch0085s0000li0131">131</link>). Sensitivity and specificity have not been determined for detection of <emphasis>A. phagocytophilum</emphasis>, while the sensitivity of detecting active <emphasis>E. chaffeensis</emphasis> infection with examination of bone marrow is only 40% (<link linkend="ch0085s0000li0124">124</link>). A monoclonal antibody can specifically detect <emphasis>E. chaffeensis</emphasis> in human tissues (<link linkend="ch0085s0000li0132">132</link>), but most studies use polyclonal antibodies which react with other <emphasis>Ehrlichia</emphasis> species. Commercial assays for these organisms are not currently available.</para>
      </sect2>
      <sect2 id="ch0085s0013s0003">
        <title>Nucleic Acid Amplification Tests</title>
        <anchor id="ch0085s0013a0004"/>
        <anchor id="ch0085s0000a0044"/>
        <para id="ch0085s0000p0050">Amplification and detection of DNA extracted from whole-blood specimens constitute a highly accurate method for laboratory diagnosis of acute<emphasis>A. phagocytophilum</emphasis> and <emphasis>E. chaffeensis</emphasis> infection, with sensitivities equal to or exceeding that of culture and blood smear evaluation (<link linkend="ch0085s0000li0045">45</link>, <link linkend="ch0085s0000li0099">99</link>). PCR is the most common amplification modality in these tests.</para>
        <sect3 id="ch0085s0013s0001">
          <title>Anaplasma phagocytophilum</title>
          <anchor id="ch0085s0013a0005"/>
          <anchor id="ch0085s0000a0045"/>
          <para id="ch0085s0000p0051">Multiple PCR assays for detection of<emphasis>A. phagocytophilum</emphasis> nucleic acids have been published, including conventional and real-time methods (<link linkend="ch0085s0000li0063">63</link>, <link linkend="ch0085s0000li0133">133</link>–<link linkend="ch0085s0000li0136">136</link>). PCR is at least as sensitive as blood smears for detection of morulae in the first 14 days after onset of illness and is more sensitive for a longer period of time (&gt;14 to ≤30 days) after illness onset (<link linkend="ch0085s0000li0123">123</link>). Many protocols utilize amplification of the 16S rRNA gene. A frequently applied and evaluated conventional method employs primers to amplify a 919-bp 16S rRNA gene fragment, usually in a single-stage reaction with or without a hybridization probe to enhance sensitivity (<link linkend="ch0085s0000li0012">12</link>, <link linkend="ch0085s0000li0134">134</link>). A previously popular alternative uses nested PCR with an outer set of primers to amplify bacterial 16S rRNA genes, followed by PCR with internal nested <emphasis>A. phagocytophilum</emphasis>-specific primers (<link linkend="ch0085s0000li0104">104</link>, <link linkend="ch0085s0000li0135">135</link>). In studies conducted prior to the development of real-time PCR, the analytical sensitivity and specificity of several published primer sets were evaluated using DNA extracted from serial dilutions of <emphasis>A. phagocytophilum</emphasis>-infected HL-60 cells (<link linkend="ch0085s0000li0135">135</link>). Specificity was evaluated using DNA extracted from cultures of <emphasis>E. chaffeensis, Rickettsia rickettsii</emphasis>, and <emphasis>Bartonella henselae.</emphasis> The primer sets with the greatest sensitivity and specificity were those used in nested PCR to amplify the 16S rRNA gene and those amplifying <emphasis>msp2</emphasis> (<link linkend="ch0085s0000li0135">135</link>). Both PCR assays detected as few as 50 infected cells/mL. Real-time PCR assays provide increased sensitivity to as few as 1 infected cell per microliter of blood. One described multiplex real-time TaqMan reverse transcriptase PCR targeting the 16S rRNA gene detects 3 <emphasis>Ehrlichia</emphasis> and 2 <emphasis>Anaplasma</emphasis> spp. and has an analytical sensitivity of 100 16S rRNA copies (approximately 1 infected cell in a test sample) (<link linkend="ch0085s0000li0133">133</link>). Another described multiplex real-time assay with similar analytical sensitivity targets <emphasis>Anaplasmataceae groEL</emphasis> and uses hybridization probes and melting temperature analysis to detect and differentiate <emphasis>E. chaffeensis, E. ewingii, E. muris</emphasis>, and <emphasis>A. phagocytophilum</emphasis> (<link linkend="ch0085s0000li0123">123</link>, <link linkend="ch0085s0000li0137">137</link>). More recently, a novel high-definition multiplex PCR assay for 12 tick-borne pathogens (ChromaCode, Carlsbad, CA), including <emphasis>A. phagocytophilum</emphasis> (<emphasis>rpoB</emphasis> gene target) and 3 <emphasis>Ehrlichia</emphasis> species (three different outer membrane protein gene targets), was evaluated using 530 whole-blood samples (<link linkend="ch0085s0000li0138">138</link>). The authors showed identical sensitivity for detection of <emphasis>A. phagocytophilum</emphasis> compared to a conventional, single-target PCR assay, with the added benefit of testing for multiple pathogens simultaneously. While there are currently no tests for <emphasis>in vitro</emphasis> diagnosis cleared or approved by the U.S. Food and Drug Administration (FDA), some CE-marked kits are available, including those by Liferiver (Brussels, Belgium), EliGene (Czech Republic), and Bioron Diagnostics (Ludwigshafen, Germany), and InterLabService (Moscow, Russia) markets a multiplex pathogen kit (AmpliSens) for detection of <emphasis>B. burgdorferi, A. phagocytophilum, E. chaffeensis</emphasis>, and <emphasis>E. muris.</emphasis> Kits designated for research use only (RUO) are also commercially available.</para>
        </sect3>
        <sect3 id="ch0085s0013s0002">
          <title>Ehrlichia chaffeensis</title>
          <anchor id="ch0085s0013a0006"/>
          <anchor id="ch0085s0000a0046"/>
          <para id="ch0085s0000p0052">There are a large number of potential gene targets for molecular detection of infection with<emphasis>E. chaffeensis</emphasis>, with PCR sensitivities ranging from 60% to 100% (<link linkend="ch0085s0000li0082">82</link>, <link linkend="ch0085s0000li0104">104</link>, <link linkend="ch0085s0000li0117">117</link>). The most widely used method is PCR amplification of DNA from <emphasis>E. chaffeensis</emphasis> in clinical samples using the HE1/HE3 primer set (<link linkend="ch0085s0000li0104">104</link>, <link linkend="ch0085s0000li0139">139</link>, <link linkend="ch0085s0000li0140">140</link>). This primer pair amplifies a 389-bp fragment of the 16S rRNA gene. The product can then be detected by simple nucleic acid staining (e.g., ethidium bromide) after agarose gel electrophoresis, by Southern hybridization of the amplified products using an internal probe, or preferably by real-time PCR (<link linkend="ch0085s0000li0141">141</link>). A clinical evaluation of <emphasis>E. chaffeensis</emphasis> PCR targeting the 16S rRNA gene showed a sensitivity of 79 to 100% compared with that of serology; however, nucleic acids from <emphasis>E. chaffeensis</emphasis> were frequently detected in patients who never developed antibodies due to collection of sera during the acute stage of disease (<link linkend="ch0085s0000li0104">104</link>, <link linkend="ch0085s0000li0140">140</link>). A nested PCR assay with 16S rRNA gene primers followed by a second (nested) reaction on whole blood yielded results similar to those obtained by culture (<link linkend="ch0085s0000li0104">104</link>). More recently, using a multiplex quantitative real-time PCR assay for detection of multiple vector-borne pathogens, including targeting the <emphasis>vlpt</emphasis> gene from <emphasis>E. chaffeensis</emphasis>, Reller and Dumler documented high sensitivity (84%) and excellent specificity (100%) for ehrlichiosis across different blood fractions collected during the acute febrile period (<link linkend="ch0085s0000li0142">142</link>). Other targets for PCR that have not been fully evaluated for clinical sensitivity or specificity include the outer-surface variable-length PCR target protein gene present in <emphasis>E. chaffeensis</emphasis> (<link linkend="ch0085s0000li0104">104</link>, <link linkend="ch0085s0000li0108">108</link>, <link linkend="ch0085s0000li0136">136</link>), the TRP120 gene, which encodes an immunodominant antigen with tandemly repeated subunits that vary among <emphasis>E. chaffeensis</emphasis> isolates, the quinolinate synthase A gene (<emphasis>nadA</emphasis>), the disulfide bond formation protein gene (<emphasis>dsb</emphasis>), and the p28 multigene family (<link linkend="ch0085s0000li0108">108</link>, <link linkend="ch0085s0000li0136">136</link>, <link linkend="ch0085s0000li0143">143</link>, <link linkend="ch0085s0000li0144">144</link>).</para>
          <anchor id="ch0085s0000a0047"/>
          <beginpage pagenum="1303"/>
          <para id="ch0085s0000p0053">Real-time PCR assays have also been developed that exhibit extremely high analytical sensitivity and specificity comparable to those of nested PCR (<link linkend="ch0085s0000li0133">133</link>, <link linkend="ch0085s0000li0143">143</link>). Advantages of real-time over conventional PCR include improved specificity (lower risk of contamination), increased speed to result, lower cost, and the ability to detect multiple <emphasis>Anaplasmataceae</emphasis> pathogens simultaneously. A broad-range real-time PCR assay that targets <emphasis>groEL</emphasis> of <emphasis>E. chaffeensis, A. phagocytophilum</emphasis>, and <emphasis>E. ewingii</emphasis> has shown excellent clinical sensitivity and specificity and also detects <emphasis>E. muris</emphasis> (<link linkend="ch0085s0000li0063">63</link>, <link linkend="ch0085s0000li0137">137</link>). While there are currently no FDA-cleared or -approved tests, CE-marked kits are available, including those by Bioron Diagnostics (Ludwigshafen, Germany) and InterLabService (Moscow, Russia; multiplex pathogen kit for detection of <emphasis>B. burgdorferi, A. phagocytophilum, E. chaffeensis</emphasis>, and <emphasis>E. muris</emphasis>).</para>
        </sect3>
        <sect3 id="ch0085s0013s0003">
          <title>Metagenomic Next-Generation Sequencing</title>
          <anchor id="ch0085s0013a0007"/>
          <anchor id="ch0085s0000a0048"/>
          <para id="ch0085s0000p0054">Although not currently a routinely used method,<emphasis>A. phagocytophilum</emphasis> and <emphasis>Ehrlichia</emphasis> species have been detected via targeted and shotgun metagenomic next-generation sequencing (mNGS) assays (<link linkend="ch0085s0000li0074">74</link>). The advantage that these assays provide, particularly with respect to shotgun mNGS, include use of a single method to detect multiple cotransmitted pathogens and the potential to identify novel pathogens. The primary challenges to routinely pursuing such testing, however, are the high cost and complexity associated with NGS-based assays, long turnaround times, limited availability, and the absence of FDA-cleared assays for tick-borne pathogens (<link linkend="ch0085s0000li0145">145</link>). Targeted NGS for bacterial pathogens, including tick-borne agents, involves initial amplification of conserved regions in the 16S rRNA gene, specifically the highly conserved and slowly evolving V1 to V3 regions. Amplicons are subsequently sequenced using NGS methods, with resulting reads assembled and pathogen sequences identified via utilization of different bioinformatic platforms and curated databases. Two targeted NGS methods, amplifying either the V1-V2 or V1-V3 16S rRNA regions, have now been described and have documented both the possibility of detecting bacterial tick-borne pathogens in whole blood, including <emphasis>A. phagocytophilum</emphasis> and <emphasis>Ehrlichia</emphasis> species, and the noninferior sensitivity of this approach compared to targeted PCR assays (<link linkend="ch0085s0000li0074">74</link>, <link linkend="ch0085s0000li0145">145</link>, <link linkend="ch0085s0000li0146">146</link>).</para>
        </sect3>
      </sect2>
    </sect1>
    <sect1 id="ch0085s0014">
      <title>Isolation Procedures</title>
      <anchor id="ch0085s0014a0001"/>
      <anchor id="ch0085s0000a0049"/>
      <para id="ch0085s0000p0055">As mentioned above, culture for these tick-borne pathogens is not used in the clinical microbiology laboratory. Both<emphasis>A. phagocytophilum</emphasis> and <emphasis>Ehrlichia</emphasis> spp. are BSL-2 agents. <emphasis>A. phagocytophilum</emphasis> has been cultivated more often from human patients than <emphasis>E. chaffeensis, E. canis, E. muris</emphasis> subsp. <emphasis>eauclairensis</emphasis>, or <emphasis>N. sennetsu</emphasis>, probably owing to the quantity of organisms present in the peripheral blood of infected patients (<link linkend="ch0085s0000li0126">126</link>). Since <emphasis>A. phagocytophilum</emphasis> and <emphasis>Ehrlichia</emphasis> species are bacteria, antibiotics in the medium must be avoided. Instructions for isolation of <emphasis>A. phagocytophilum</emphasis> and <emphasis>Ehrlichia</emphasis> spp. can be found in previous editions of this <emphasis>Manual</emphasis> and the published literature (<link linkend="ch0085s0000li0118">118</link>, <link linkend="ch0085s0000li0120">120</link>, <link linkend="ch0085s0000li0121">121</link>).</para>
    </sect1>
    <sect1 id="ch0085s0015">
      <title>Serologic Tests</title>
      <anchor id="ch0085s0015a0001"/>
      <anchor id="ch0085s0000a0050"/>
      <para id="ch0085s0000p0056">The gold standard method for serodiagnosis of anaplasmosis and<emphasis>E. chaffeensis</emphasis> ehrlichiosis is demonstration of seroconversion or a 4-fold rise in IgG titers by examination of paired (acute- and convalescent-phase) sera using indirect immunofluorescence assays (IFAs). The IFA employs slides with individual wells containing <emphasis>A. phagocytophilum</emphasis>- or <emphasis>E. chaffeensis</emphasis>-infected cells, which are incubated with patient sera. If present, specific antibodies in the serum sample bind to the bacterial antigens and are subsequently detected using a fluorescently labeled secondary antibody. The test is interpreted visually by technologists using fluorescent microscopy, which can be subjective and therefore requires significant training and expertise. Samples in each well are interpreted as positive if (i) the fluorescent output is of sufficient intensity compared to controls, (ii) the appropriate proportion of infected cells have reactivity, and (iii) a characteristic fluorescence pattern (i.e., clumps representative of classic intracytoplasmic morulae) is observed (<anchor id="ch0085s0000a0051"/><link linkend="ch0085s0000a0053">Fig. 3</link>). Samples are typically screened at one or two dilutions, after which positive samples are serially diluted to achieve an endpoint titer. As with most serologic assays, sensitivity is low during the first week of infection (Table 2), which is when most patients present for medical evaluation (<link linkend="ch0085s0000li0045">45</link>). Sensitivity increases with time, however, with most individuals being seropositive 2 to 3 weeks after symptom onset.</para>
      <para id="ch0085s0000p0057">There is significant antibody cross-seroreactivity between<emphasis>Ehrlichia</emphasis> species, and also between antibodies to <emphasis>A. phagocytophilum</emphasis> and <emphasis>E. chaffeensis</emphasis>, although titers of antibody to the infecting bacterium are generally higher. Thus, screening for antibodies against both bacteria is recommended when anaplasmosis or <emphasis>E. chaffeensis</emphasis> ehrlichiosis is suspected. IgG-class antibodies can persist for months to years after resolution of infection and may be found in a high percentage of healthy individuals living in areas of endemicity (<link linkend="ch0085s0000li0045">45</link>).</para>
      <anchor id="ch0085s0000a0052"/>
      <beginpage pagenum="1304"/>
      <figure id="ch0085s0000f0003"><title><phrase role="figureLabel"><anchor id="ch0085s0000a0053"/><link linkend="ch0085s0000a0051">FIGURE 3</link></phrase> Immunofluorescence assay for (A) <emphasis>A. phagocytophilum</emphasis> and (B) <emphasis>E. chaffeensis.</emphasis> (Focus Diagnostics, DiaSorin Molecular LLC, USA). Morulae fluoresce green (arrow) due to use of a fluorescein-labeled secondary anti-human IgG antibody, whereas infected eukaryotic cells fluoresce red because of Evans blue counterstain.</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0085f03.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
    </sect1>
    <sect1 id="ch0085s0016">
      <title>Anaplasma phagocytophilum</title>
      <anchor id="ch0085s0016a0001"/>
      <anchor id="ch0085s0000a0054"/>
      <para id="ch0085s0000p0058">The preferred method for serologic testing of human sera is the use of HL-60 promyelocyte cells infected with a human<emphasis>A. phagocytophilum</emphasis> isolate (<link linkend="ch0085s0000li0118">118</link>, <link linkend="ch0085s0000li0147">147</link>–<link linkend="ch0085s0000li0151">151</link>). Commercial sources of IFA serodiagnostic kits include Focus Diagnostics (DiaSorin Molecular LLC, Cypress, CA), Scimedx Corporation (Dover, NJ), Biocell Diagnostics (Baltimore, MD), and Fuller Laboratories (Fullerton, CA); the assays are not FDA cleared or approved in the United States, although they are CE marked. Enzyme-linked immunosorbent assay (ELISA) and immunoblot methods for serodiagnosis have been described (<link linkend="ch0085s0000li0010">10</link>, <link linkend="ch0085s0000li0147">147</link>, <link linkend="ch0085s0000li0150">150</link>); however, they are not routinely used due to limited understanding of their performance characteristics and availability. Also, technologies that use immunoblot confirmation or commercially prepared recombinant <emphasis>A. phagocytophilum</emphasis> Msp2 proteins or peptides in devices that enable rapid detection have been employed for serologic diagnosis in veterinary laboratories, but they have not been evaluated for diagnosis of human infections (<link linkend="ch0085s0000li0152">152</link>, <link linkend="ch0085s0000li0153">153</link>). Although anti-<emphasis>A. phagocytophilum</emphasis> IgM and IgG IFA kits are available, IgG testing is most beneficial. IgM testing is potentially useful for identification of recent infection, but neither the sensitivity nor the specificity is as high as that for testing paired sera for IgG, and questions about IgM specificity led the CDC to discourage its use as a single test (<link linkend="ch0085s0000li0154">154</link>). As a result, and because of the availability and increased sensitivity of PCR assays during acute infection, IgM testing is not commonly used or recommended (<link linkend="ch0085s0000li0151">151</link>).</para>
      <para id="ch0085s0000p0059">For IgG testing, sera are typically screened at a single dilution (1:64 or 1:80), and if specimens are reactive, they are serially diluted to determine the endpoint titer. A serodiagnostic confirmation is achieved when a 4-fold rise in titer is demonstrated in convalescent-phase sera, with a minimum IgG titer of ≥1:128 (<link linkend="ch0085s0000li0115">115</link>). Demonstration of a single high IgG antibody titer (≥1:128, or higher for residents of regions of endemicity) in a patient with typical clinical features of anaplasmosis may also be used to support a diagnosis of anaplasmosis (<link linkend="ch0085s0000li0129">129</link>, <link linkend="ch0085s0000li0155">155</link>). Approximately 25 to 45% of infected patients have antibodies at the time of presentation (<link linkend="ch0085s0000li0129">129</link>, <link linkend="ch0085s0000li0149">149</link>, <link linkend="ch0085s0000li0155">155</link>, <link linkend="ch0085s0000li0156">156</link>); however, in regions where anaplasmosis is endemic, up to 11 to 14% of the population possess antibodies, rendering a single serologic test less useful (<link linkend="ch0085s0000li0052">52</link>, <link linkend="ch0085s0000li0053">53</link>). The typical response during acute infection is a rapid rise (within 2 weeks of onset) in antibody levels, reaching high titers (≥1:640) within the first month (<link linkend="ch0085s0000li0149">149</link>, <link linkend="ch0085s0000li0156">156</link>). In treated patients whose diagnoses were confirmed by culture, antibody titers declined gradually over several months, and about half had antibodies detectable by IFA 1 year after infection. However, many patients have antibodies detectable for months to years after initial infection (<link linkend="ch0085s0000li0156">156</link>).</para>
      <para id="ch0085s0000p0060">The sensitivity and specificity of the anaplasmosis serologic tests are both believed to be high because of good correlation between typical clinical cases and serologic reactions to<emphasis>A. phagocytophilum</emphasis> group antigens (<link linkend="ch0085s0000li0129">129</link>, <link linkend="ch0085s0000li0149">149</link>, <link linkend="ch0085s0000li0156">156</link>). Seroconversion was documented for 21 of 23 patients (91.3%) with culture-confirmed anaplasmosis, from whom a convalescent-phase sample was available (<link linkend="ch0085s0000li0149">149</link>). In an inter- and intralaboratory evaluation, paired serology had a median sensitivity of 95% for the detection of acute anaplasmosis in a group of 28 patients diagnosed by culture, PCR, or the presence of morulae in blood smears (<link linkend="ch0085s0000li0151">151</link>). Of note, patients with anaplasmosis have serologic reactions to <emphasis>E. chaffeensis</emphasis> in up to 15% of cases but often show the higher titers with <emphasis>A. phagocytophilum</emphasis> antigens (<link linkend="ch0085s0000li0129">129</link>, <link linkend="ch0085s0000li0151">151</link>).</para>
      <para id="ch0085s0000p0061">Cross-reactivity in the<emphasis>A. phagocytophilum</emphasis> IFA may occur in patients infected with other rickettsiae, <emphasis>Coxiella burnetii</emphasis> (Q fever), and Epstein-Barr virus. Importantly, due to geographic cocirculation of many tick-borne pathogens, which are carried by the same tick vectors, the risk of cotransmission of <emphasis>A. phagocytophilum</emphasis> and other tick-borne pathogens is not insignificant. Across studies, the frequency of <emphasis>A. phagocytophilum</emphasis> and Lyme disease coinfections ranges from 2.3% to 13%, depending on diagnostic criteria and region (<link linkend="ch0085s0000li0157">157</link>, <link linkend="ch0085s0000li0158">158</link>). As a result, antibodies to multiple agents are common in individuals living in areas of high endemicity (<link linkend="ch0085s0000li0052">52</link>, <link linkend="ch0085s0000li0159">159</link>). Autoantibodies to platelets and other leukocyte components can cause false-positive IFA tests for many pathogens, including <emphasis>A. phagocytophilum</emphasis> (<link linkend="ch0085s0000li0160">160</link>). Prescreening for autoantibodies or routine removal of rheumatoid factors will lessen the risk of misinterpretation due to antibodies reactive with cellular components, including nuclear or cytoplasmic antigens that could have the morphologic appearance of morulae. Finally, antigenic diversity exists among isolates of <emphasis>A. phagocytophilum</emphasis> but is not generally thought to affect antibody detection in clinical specimens (<link linkend="ch0085s0000li0151">151</link>, <link linkend="ch0085s0000li0161">161</link>).</para>
    </sect1>
    <sect1 id="ch0085s0017">
      <title>Ehrlichia chaffeensis</title>
      <anchor id="ch0085s0017a0001"/>
      <anchor id="ch0085s0000a0055"/>
      <para id="ch0085s0000p0062">Similar to<emphasis>A. phagocytophilum</emphasis>, antibodies against <emphasis>E. chaffeensis</emphasis> are most commonly detected by IFA. The cell type usually employed is <emphasis>E. chaffeensis</emphasis> Arkansas strain-infected DH82 canine macrophage-like cells. Originally, <emphasis>E. canis</emphasis> was used to detect serologic responses to <emphasis>E. chaffeensis</emphasis> due to the known serologic cross-reactivity between the two species; however, IFA reagents for use with <emphasis>E. chaffeensis</emphasis>-infected cells are now readily available and should be used for clinical testing (<link linkend="ch0085s0000li0162">162</link>). These include IFA kits from Focus Technologies (DiaSorin Molecular LLC, Cypress, CA), Biocell Diagnostics (Baltimore, MD), Fuller Laboratories (Fullerton, CA), and Scimedx Corporation (Denville, NJ). The role of immunoblots in diagnosis of <emphasis>E. chaffeensis</emphasis> ehrlichiosis is not well established, and their use cannot be advocated. Alternative methods based on recombinant proteins and synthetic peptides show promise, but these are not commercially available (<link linkend="ch0085s0000li0163">163</link>–<link linkend="ch0085s0000li0165">165</link>). As with anaplasmosis, detection of IgG-class antibodies to <emphasis>E. chaffeensis</emphasis> is more beneficial than assessment for IgM-class antibodies. A systematic evaluation of the usefulness of IgM testing has not been conducted, but preliminary data from nine culture-confirmed cases suggest that it might be slightly more sensitive than IgG for the diagnosis of <emphasis>E. chaffeensis</emphasis> ehrlichiosis during the acute phase (<link linkend="ch0085s0000li0166">166</link>). However, because of concerns about specificity and the routine availability of more sensitive PCR assays, IgM testing is not currently recommended for routine diagnosis of recent <emphasis>E. chaffeensis</emphasis> ehrlichiosis (<link linkend="ch0085s0000li0154">154</link>).</para>
      <para id="ch0085s0000p0063">Similar to the approach for<emphasis>A. phagocytophilum</emphasis> serologic testing, samples are initially screened at a dilution of 1:64 or 1:80 for IgG antibodies to <emphasis>E. chaffeensis.</emphasis> Reactive samples are subsequently serially diluted to determine an endpoint. Seroconversion or a 4-fold increase in IgG antibody titers confirms the diagnosis of <emphasis>E. chaffeensis</emphasis> ehrlichiosis. A single high IgG titer, ≥1:128, provides supportive evidence of acute infection in patients with a compatible clinical presentation (<link linkend="ch0085s0000li0115">115</link>). Acute-phase sera should be obtained at the time of presentation, and convalescent-phase sera are best obtained 3 to 6 weeks thereafter.</para>
      <anchor id="ch0085s0000a0056"/>
      <beginpage pagenum="1305"/>
      <para id="ch0085s0000p0064">The sensitivity and specificity of IFA for the diagnosis of infection with<emphasis>E. chaffeensis</emphasis> have not been clearly established; however they are assumed to be high because of documented correlation between new or rising antibody titers against <emphasis>E. chaffeensis</emphasis> and characteristic clinical findings (<link linkend="ch0085s0000li0077">77</link>). In the early phase of infection, IFA testing is not sensitive compared to PCR (Table 2) (<link linkend="ch0085s0000li0166">166</link>). Presumptive false-positive reactions have been detected in patients diagnosed with <emphasis>Rickettsia, C. burnetii, Brucella</emphasis>, Lyme disease, and Epstein-Barr virus infections (<link linkend="ch0085s0000li0162">162</link>, <link linkend="ch0085s0000li0167">167</link>). The presence of autoantibodies can also result in false-positive results.</para>
      <para id="ch0085s0000p0065">Antigenic diversity among<emphasis>E. chaffeensis</emphasis> isolates has been well described (<link linkend="ch0085s0000li0168">168</link>), but it may not affect the detection of polyclonal antibody responses generated with human infection. Several reports describe patients with suspected <emphasis>E. chaffeensis</emphasis> ehrlichiosis who lacked antibody responses, even long after onset of symptoms (<link linkend="ch0085s0000li0104">104</link>, <link linkend="ch0085s0000li0140">140</link>, <link linkend="ch0085s0000li0169">169</link>). However, in the few cases in which <emphasis>E. chaffeensis</emphasis> infection was proven by isolation of the agent, patients who survived developed clear convalescent-phase serologic reactions by IFA (<link linkend="ch0085s0000li0068">68</link>, <link linkend="ch0085s0000li0104">104</link>, <link linkend="ch0085s0000li0108">108</link>, <link linkend="ch0085s0000li0169">169</link>, <link linkend="ch0085s0000li0170">170</link>). Hypothetical reasons for false-negative results include infection by antigenically diverse strains (unproven) and abrogation of antibody response by early therapy (<link linkend="ch0085s0000li0104">104</link>). Antibodies developed following infection with other <emphasis>Ehrlichia</emphasis> species may cross-react in <emphasis>E. chaffeensis</emphasis> IFAs; however, the level of cross-reactivity is not well established or consistent among patients, as most recently documented with identification of <emphasis>E. muris</emphasis> subsp. <emphasis>eauclairensis</emphasis> (<link linkend="ch0085s0000li0063">63</link>).</para>
      <sect2 id="ch0085s0017s0001">
        <title>ANTIMICROBIAL SUSCEPTIBILITIES, TREATMENT, AND PREVENTION</title>
        <anchor id="ch0085s0017a0002"/>
        <anchor id="ch0085s0000a0057"/>
        <para id="ch0085s0000p0066">Doxycycline is the drug of choice for treatment of rickettsial infections in both children and adults (<link linkend="ch0085s0000li0045">45</link>, <link linkend="ch0085s0000li0171">171</link>). No prospective controlled treatment trials to determine antimicrobial effectiveness for ehrlichiosis or anaplasmosis have been conducted. However, retrospective studies and observations from routine clinical practice demonstrate that patients with <emphasis>E. chaffeensis</emphasis> ehrlichiosis and anaplasmosis defervesce generally within 48 h of therapy with doxycycline (<link linkend="ch0085s0000li0041">41</link>, <link linkend="ch0085s0000li0077">77</link>, <link linkend="ch0085s0000li0172">172</link>). Tetracyclines are uniformly bactericidal for <emphasis>Ehrlichia</emphasis> and <emphasis>Anaplasma</emphasis> species, whereas the MIC of chloramphenicol cannot be safely achieved in humans with <emphasis>E. chaffeensis</emphasis> ehrlichiosis or anaplasmosis (<link linkend="ch0085s0000li0173">173</link>–<link linkend="ch0085s0000li0177">177</link>). Of note, many antibiotics prescribed for undifferentiated fever, such as penicillins, cephalosporins, aminoglycosides, and macrolides, do not inhibit the growth of ehrlichiae <emphasis>in vitro.</emphasis> The rifamycins (rifampin and rifabutin) can achieve effective inhibition or killing of <emphasis>Ehrlichia</emphasis> and <emphasis>Anaplasma</emphasis> species <emphasis>in vitro</emphasis>, and the fluoroquinolones (ofloxacin and levofloxacin) have very low MICs for human isolates of <emphasis>A. phagocytophilum</emphasis> (<link linkend="ch0085s0000li0175">175</link>, <link linkend="ch0085s0000li0177">177</link>). However, at least one report documents recrudescence of infection with <emphasis>A. phagocytophilum</emphasis> after levofloxacin was discontinued, followed by a subsequent clinical response to doxycycline (<link linkend="ch0085s0000li0178">178</link>–<link linkend="ch0085s0000li0180">180</link>). Rifampin has been used successfully in patients for whom tetracyclines cannot be used or for whom an alternative is preferred, including pregnant women and children (<link linkend="ch0085s0000li0178">178</link>, <link linkend="ch0085s0000li0180">180</link>). <emphasis>In vitro</emphasis> susceptibility testing by real-time PCR found that <emphasis>E. chaffeensis</emphasis> was susceptible to doxycycline and rifampin and was partially susceptible to the fluoroquinolones. Resistance to macrolides, trimethoprim-sulfamethoxazole, and beta-lactam compounds was confirmed (<link linkend="ch0085s0000li0173">173</link>).</para>
        <para id="ch0085s0000p0067">Whereas persistent infections with<emphasis>Ehrlichia</emphasis> and <emphasis>Anaplasma</emphasis> species can occur in naturally and experimentally infected animals even after treatment with tetracycline, persistence of these bacteria in humans is rarely documented and is not believed to have any clinical importance (<link linkend="ch0085s0000li0169">169</link>, <link linkend="ch0085s0000li0181">181</link>, <link linkend="ch0085s0000li0182">182</link>). Therapy is usually highly effective at eliminating them from the blood of infected humans.</para>
        <para id="ch0085s0000p0068">Prevention of human anaplasmosis and ehrlichiosis is through avoidance of tick bites and prompt removal of attached ticks (<link linkend="ch0085s0000li0045">45</link>). Animal studies suggest that ticks are attached to their host for 24 to 48 h prior to transmission of <emphasis>A. phagocytophilum</emphasis>, and thus, removing ticks as soon as possible may decrease the risk of transmission (<link linkend="ch0085s0000li0045">45</link>); however, at least one study demonstrated transmission within 4 h of a tick bite (<link linkend="ch0085s0000li0183">183</link>). No similar data are available for <emphasis>E. chaffeensis</emphasis> or <emphasis>E. ewingii</emphasis> transmission. Multiple measures for prevention of tick bites have been described including use of repellents (e.g., DEET [<emphasis>N</emphasis>,<emphasis>N</emphasis>-diethyl-<emphasis>meta</emphasis>-toluamide]), environmental modifications, and use of protective or permethrin-treated clothing (<link linkend="ch0085s0000li0045">45</link>). Various ectoparasite control measures are also available for pets and livestock, including the application of topical acaricides (<link linkend="ch0085s0000li0045">45</link>).</para>
      </sect2>
      <sect2 id="ch0085s0017s0002">
        <title>EVALUATION, INTERPRETATION, AND REPORTING OF RESULTS</title>
        <anchor id="ch0085s0017a0003"/>
        <anchor id="ch0085s0000a0058"/>
        <para id="ch0085s0000p0069">Identification of<emphasis>Ehrlichia</emphasis> and <emphasis>Anaplasma</emphasis> species infections requires clinical suspicion, guided by symptom manifestation and geographic exposure risk, followed by laboratory confirmation. Since rapid specific diagnosis is infrequently possible, empirical therapy with doxycycline should be initiated when the diagnosis is suspected, since delays may lead to increased morbidity and perhaps mortality (<link linkend="ch0085s0000li0045">45</link>, <link linkend="ch0085s0000li0112">112</link>). Collection of diagnostic samples should ideally occur before therapy is initiated, and patients should be encouraged to return for clinical and serologic follow-up 2 to 4 weeks later for collection of a convalescent-phase serum sample.</para>
        <para id="ch0085s0000p0070">The presence of intracytoplasmic inclusions within a leukocyte in peripheral blood is helpful when present but lacks sensitivity and specificity (<link linkend="ch0085s0000li0045">45</link>, <link linkend="ch0085s0000li0099">99</link>). If the typical morphology of an <emphasis>Ehrlichia</emphasis> or <emphasis>Anaplasma</emphasis> morula is observed, an assessment as to the hematopoietic lineage that contains morulae should be made and reported.</para>
        <para id="ch0085s0000p0071">A positive PCR result should be reported as such, indicating the presence of<emphasis>E. chaffeensis</emphasis> or <emphasis>A. phagocytophilum</emphasis> DNA present. Laboratories that use a multiplex or broad-range PCR to identify <emphasis>Ehrlichia</emphasis> species or <emphasis>Anaplasma</emphasis> DNA in blood may also be able detect <emphasis>E. ewingii</emphasis> and <emphasis>E. muris</emphasis> subsp. <emphasis>eauclairensis</emphasis> infection that mimics either anaplasmosis or <emphasis>E. chaffeensis</emphasis> ehrlichiosis (<link linkend="ch0085s0000li0063">63</link>, <link linkend="ch0085s0000li0067">67</link>, <link linkend="ch0085s0000li0138">138</link>). Broad-range PCR assays targeting the 16S rRNA gene or <emphasis>groEL</emphasis> have also identified infection with “<emphasis>Ca.</emphasis> Neoehrlichia mikurensis” in Europe (<link linkend="ch0085s0000li0184">184</link>).</para>
        <para id="ch0085s0000p0072">IFA serologic results should be reported as the endpoint titers of antibodies determined to be reactive for<emphasis>E. chaffeensis</emphasis> or <emphasis>A. phagocytophilum</emphasis>, including the positive cutoff value used in the laboratory. The gold standard for the diagnosis of <emphasis>E. chaffeensis</emphasis> or <emphasis>A. phagocytophilum</emphasis> infection by serology is a 4-fold increase in IgG titer or documentation of seroconversion with a minimum titer of 1:128 if sample dilutions start at 1:64. An interpretation should indicate whether the titers are considered “significant” or “positive,” preferably based upon a 4-fold increase or 4-fold decrease in titer, although this is not often possible due to the submission of single-time-point samples. When only a single high serum IgG titer is obtained, the laboratory should note that it is supportive, but not confirmed evidence, of infection. The use of IgM titers alone is not advocated to establish a diagnosis, since it is not as sensitive as using IgG alone. It should be noted that infections with <emphasis>E. ewingii</emphasis> and <emphasis>E. muris</emphasis> subsp. <emphasis>eauclairensis</emphasis> may yield serologic patterns considered diagnostic for <emphasis>E. chaffeensis</emphasis> and presumably for <emphasis>A. phagocytophilum</emphasis> as well (<link linkend="ch0085s0000li0045">45</link>, <link linkend="ch0085s0000li0063">63</link>).</para>
        <anchor id="ch0085s0000a0059"/>
        <beginpage pagenum="1306"/>
        <para id="ch0085s0000p0073">Cases of ehrlichiosis and anaplasmosis in the United States should be reported using the CDC’s Tick-Borne Rickettsial Disease Case Report form (<ulink url="https://www.cdc.gov/ticks/forms/Tick_TBRD_FILL_508.pdf">https://www.cdc.gov/ticks/forms/Tick_TBRD_FILL_508.pdf</ulink>). For the purpose of surveillance, the Council of State and Territorial Epidemiologists and CDC developed a case definition that was amended in 2008 to include <emphasis>E. chaffeensis</emphasis> ehrlichiosis (HME), anaplasmosis, <emphasis>E. ewingii</emphasis> infection, and “ehrlichiosis/anaplasmosis—undetermined” (<link linkend="ch0085s0000li0185">185</link>). According to this definition, a clinically compatible case is one in which the patient presents with any reported fever and one or more of the following: headache, myalgia, anemia, leukopenia, thrombocytopenia, or any hepatic transaminase elevation. Definitive confirmation of a clinically compatible case requires (i) a 4-fold change in endpoint titers of IgG to <emphasis>E. chaffeensis</emphasis> or <emphasis>A. phagocytophilum</emphasis> by IFA in paired serum samples, (ii) positive PCR for <emphasis>E. chaffeensis</emphasis> or <emphasis>A. phagocytophilum</emphasis> DNA, (iii) detection of <emphasis>E. chaffeensis</emphasis> or <emphasis>A. phagocytophilum</emphasis> antigen in a biopsy or autopsy sample by immunostaining, or (iv) culture of <emphasis>E. chaffeensis</emphasis> or <emphasis>A. phagocytophilum</emphasis> from a clinical sample. A clinically compatible case with (i) a single IFA titer of ≥1:64 of IgG to <emphasis>E. chaffeensis</emphasis> or <emphasis>A. phagocytophilum</emphasis> or (ii) identification of morulae in monocytes (HME) or neutrophils (anaplasmosis) is classified as probable ehrlichiosis/anaplasmosis. The CDC does not use IgM test results as independent diagnostic support criteria. The diagnosis of <emphasis>E. ewingii, E. muris</emphasis> subsp. <emphasis>eauclairensis</emphasis>, and “<emphasis>Ca.</emphasis> Neoehrlichia mikurensis” infection can be established only by nucleic acid amplification methods, since specific antigens and serologic methods are not available. A diagnosis of “ehrlichiosis or anaplasmosis—undetermined” is used when serological tests cannot distinguish between infection by <emphasis>E. chaffeensis</emphasis> or <emphasis>A. phagoc</emphasis><emphasis>ytophilum</emphasis>.</para>
        <para id="ch0085s0000p0074">Finally, clinicians should consider the possibility of tick-borne coinfections, particularly in patients who fail to respond to antimicrobial therapy directed to<emphasis>A. phagocytophilum</emphasis> and <emphasis>Ehrlichia</emphasis> species. In particular, <emphasis>Babesia microti</emphasis> and Powassan virus may be transmitted by <emphasis>I. scapularis</emphasis>, the same tick that transmits <emphasis>A. phagocytophilum</emphasis>, and neither infection responds to doxycycline.</para>
        <para id="ch0085s0000p0075">We recognize the contributions of J. Stephen Dumler and Megan E. Reller to this chapter.</para>
      </sect2>
      <sect2 id="ch0085s0017s0003">
        <title>REFERENCES</title>
        <anchor id="ch0085s0017a0004"/>
        <anchor id="ch0085s0000a0060"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0085s0000li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Dumler JS, Barbet AF, Bekker CP, Dasch GA, Palmer GH, Ray SC, Rikihisa Y, Rurangirwa FR.</emphasis> 2001. Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of <citetitle><emphasis>Ehrlichia</emphasis></citetitle> with <citetitle><emphasis>Anaplasma</emphasis></citetitle>, <citetitle><emphasis>Cowdria</emphasis></citetitle> with <citetitle><emphasis>Ehrlichia</emphasis></citetitle> and <citetitle><emphasis>Ehrlichia</emphasis></citetitle> with <citetitle><emphasis>Neorickettsia</emphasis></citetitle>, descriptions of six new species combinations and designation of <citetitle><emphasis>Ehrlichia equi</emphasis></citetitle> and ‘HGE agent’ as subjective synonyms of <citetitle><emphasis>Ehrlichia phagocytophila. Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>2145–2165.</para>
          </listitem>
          <listitem id="ch0085s0000li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Maeda K, Markowitz N, Hawley RC, Ristic M, Cox D, McDade JE.</emphasis> 1987. Human infection with <citetitle><emphasis>Ehrlichia canis</emphasis></citetitle>, a leukocytic rickettsia. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">316</emphasis><emphasis role="strong">:</emphasis>853–856.</para>
          </listitem>
          <listitem id="ch0085s0000li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Anderson BE, Dawson JE, Jones DC, Wilson KH.</emphasis> 1991. <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle>, a new species associated with human ehrlichiosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">29:</emphasis>2838–2842.</para>
          </listitem>
          <listitem id="ch0085s0000li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Slatko BE, Luck AN, Dobson SL, Foster JM.</emphasis> 2014. <citetitle><emphasis>Wolbachia</emphasis></citetitle> endosymbionts and human disease control. <citetitle><emphasis>Mol Biochem Parasitol</emphasis></citetitle> <emphasis role="strong">195:</emphasis>88–95.</para>
          </listitem>
          <listitem id="ch0085s0000li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Kawahara M, Rikihisa Y, Isogai E, Takahashi M, Misumi H, Suto C, Shibata S, Zhang C, Tsuji M.</emphasis> 2004. Ultrastructure and phylogenetic analysis of ‘<citetitle><emphasis>Candidatus</emphasis></citetitle> Neoehrlichia mikurensis’ in the family Anaplasmataceae, isolated from wild rats and found in <citetitle><emphasis>Ixodes ovatus</emphasis></citetitle> ticks. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>1837–1843.</para>
          </listitem>
          <listitem id="ch0085s0000li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Welinder-Olsson C, Kjellin E, Vaht K, Jacobsson S, Wennerås C.</emphasis> 2010. First case of human “<citetitle><emphasis>Candidatus</emphasis></citetitle> Neoehrlichia mikurensis” infection in a febrile patient with chronic lymphocytic leukemia. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>1956–1959.</para>
          </listitem>
          <listitem id="ch0085s0000li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Manoj RRS, Latrofa MS, Epis S, Otranto D.</emphasis> 2021. <citetitle><emphasis>Wolbachia</emphasis></citetitle>: endosymbiont of onchocercid nematodes and their vectors. <citetitle><emphasis>Parasit Vectors</emphasis></citetitle> <emphasis role="strong">14:</emphasis>245.</para>
          </listitem>
          <listitem id="ch0085s0000li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Rikihisa Y, Dumler JS, Dasch GA.</emphasis> 2015. <citetitle><emphasis>Neorickettsia. In</emphasis></citetitle> Whitman WB (ed), <citetitle><emphasis>Bergey’s Manual of Systematics of Archaea and Bacteria.</emphasis></citetitle> Wiley, Hoboken, NJ.</para>
          </listitem>
          <listitem id="ch0085s0000li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Gillespie JJ, Williams K, Shukla M, Snyder EE, Nordberg EK, Ceraul SM, Dharmanolla C, Rainey D, Soneja J, Shallom JM, Vishnubhat ND, Wattam R, Purkayastha A, Czar M, Crasta O, Setubal JC, Azad AF, Sobral BS.</emphasis> 2008. <citetitle><emphasis>Rickettsia</emphasis></citetitle> phylogenomics: unwinding the intricacies of obligate intracellular life. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">3:</emphasis>e2018.</para>
          </listitem>
          <listitem id="ch0085s0000li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Dumler JS, Asanovich KM, Bakken JS, Richter P, Kimsey R, Madigan JE.</emphasis> 1995. Serologic cross-reactions among <citetitle><emphasis>Ehrlichia equi</emphasis></citetitle>, <citetitle><emphasis>Ehrlichia phagocytophila</emphasis></citetitle>, and human granulocytic <citetitle><emphasis>Ehrlichia. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>1098–1103.</para>
          </listitem>
          <listitem id="ch0085s0000li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Jongejan F, Wassink LA, Thielemans MJ, Perie NM, Uilenberg G.</emphasis> 1989. Serotypes in <citetitle><emphasis>Cowdria ruminantium</emphasis></citetitle> and their relationship with <citetitle><emphasis>Ehrlichia phagocytophila</emphasis></citetitle> determined by immunofluorescence. <citetitle><emphasis>Vet Microbiol</emphasis></citetitle> <emphasis role="strong">21:</emphasis>31–40.</para>
          </listitem>
          <listitem id="ch0085s0000li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Chen SM, Dumler JS, Bakken JS, Walker DH.</emphasis> 1994. Identification of a granulocytotropic <citetitle><emphasis>Ehrlichia</emphasis></citetitle> species as the etiologic agent of human disease. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">32</emphasis><emphasis role="strong">:</emphasis>589–595.</para>
          </listitem>
          <listitem id="ch0085s0000li0013" role="bibliographyEntry">
            <para>13.<emphasis role="strong">Massung RF, Levin ML, Munderloh UG, Silverman DJ, Lynch MJ, Gaywee JK, Kurtti TJ.</emphasis> 2007. Isolation and propagation of the Ap-Variant 1 strain of <citetitle><emphasis>Anaplasma phagocytophilum</emphasis></citetitle> in a tick cell line. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>2138–2143.</para>
          </listitem>
          <listitem id="ch0085s0000li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">Stuen S, Van De Pol I, Bergström K, Schouls LM.</emphasis> 2002. Identification of <citetitle><emphasis>Anaplasma phagocytophila</emphasis></citetitle> (formerly <citetitle><emphasis>Ehrlichia phagocytophila</emphasis></citetitle>) variants in blood from sheep in Norway. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>3192–3197.</para>
          </listitem>
          <listitem id="ch0085s0000li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Massung RF, Mauel MJ, Owens JH, Allan N, Courtney JW, Stafford KC III, Mather TN.</emphasis> 2002. Genetic variants of <citetitle><emphasis>Ehrlichia phagocytophila</emphasis></citetitle>, Rhode Island and Connecticut. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">8</emphasis><emphasis role="strong">:</emphasis>467–472.</para>
          </listitem>
          <listitem id="ch0085s0000li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Stuen S, Granquist EG, Silaghi C.</emphasis> 2013. <citetitle><emphasis>Anaplasma phagocytophilum</emphasis></citetitle>—a widespread multi-host pathogen with highly adaptive strategies. <citetitle><emphasis>Front Cell Infect Microbiol</emphasis></citetitle> <emphasis role="strong">3:</emphasis>31.</para>
          </listitem>
          <listitem id="ch0085s0000li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Dumler JS, Rikihisa Y, Dasch GA.</emphasis> 2015. <citetitle><emphasis>Anaplasmataceae. In</emphasis></citetitle> Whitman WB (ed), <citetitle><emphasis>Bergey’s Manual of Systematics of Archaea and Bacteria.</emphasis></citetitle> Wiley, Hoboken, NJ.</para>
          </listitem>
          <listitem id="ch0085s0000li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">Rikihisa Y.</emphasis> 2006. New findings on members of the family Anaplasmataceae of veterinary importance. <citetitle><emphasis>Ann N Y Acad Sci</emphasis></citetitle> <emphasis role="strong">1078</emphasis><emphasis role="strong">:</emphasis>438–445.</para>
          </listitem>
          <listitem id="ch0085s0000li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Dunning Hotopp JC, Lin M, Madupu R, Crabtree J, Angiuoli SV, Eisen JA, Seshadri R, Ren Q, Wu M, Utterback TR, Smith S, Lewis M, Khouri H, Zhang C, Niu H, Lin Q, Ohashi N, Zhi N, Nelson W, Brinkac LM, Dodson RJ, Rosovitz MJ, Sundaram J, Daugherty SC, Davidsen T, Durkin AS, Gwinn M, Haft DH, Selengut JD, Sullivan SA, Zafar N, Zhou L, Benahmed F, Forberger H, Halpin R, Mulligan S, Robinson J, White O, Rikihisa Y, Tettelin H.</emphasis> 2006. Comparative genomics of emerging human ehrlichiosis agents. <citetitle><emphasis>PLoS Genet</emphasis></citetitle> <emphasis role="strong">2:</emphasis>e21.</para>
          </listitem>
          <listitem id="ch0085s0000li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Fischer K, Tkach VV, Curtis KC, Fischer PU.</emphasis> 2017. Ultrastructure and localization of <citetitle><emphasis>Neorickettsia</emphasis></citetitle> in adult digenean trematodes provides novel insights into helminth-endobacteria interaction. <citetitle><emphasis>Parasit Vectors</emphasis></citetitle> <emphasis role="strong">10:</emphasis>177.</para>
          </listitem>
          <listitem id="ch0085s0000li0021" role="bibliographyEntry">
            <anchor id="ch0085s0000a0061"/>
            <para>21.<emphasis role="strong">Madigan JE, Pusterla N, Johnson E, Chae JS, Pusterla JB, Derock E, Lawler SP.</emphasis> 2000. Transmission of <citetitle><emphasis>Ehrlichia risticii</emphasis></citetitle>, the agent of Potomac horse fever, using naturally infected aquatic insects and helminth vectors: preliminary report. <citetitle><emphasis>Equine Vet J</emphasis></citetitle> <emphasis role="strong">32</emphasis><emphasis role="strong">:</emphasis>275–279.</para>
          </listitem>
          <listitem id="ch0085s0000li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Taylor MJ.</emphasis> 2002. <citetitle><emphasis>Wolbachia</emphasis></citetitle> endosymbiotic bacteria of filarial nematodes. A new insight into disease pathogenesis and control. <citetitle><emphasis>Arch Med Res</emphasis></citetitle> <emphasis role="strong">33</emphasis><emphasis role="strong">:</emphasis>422–424.</para>
          </listitem>
          <listitem id="ch0085s0000li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">La Scola BL, Bandi C, Raoult D.</emphasis> 2015. <citetitle><emphasis>Wolbachia. In</emphasis></citetitle> Whitman WB (ed), <citetitle><emphasis>Bergey’s Manual of Systematics of Archaea and Bacteria.</emphasis></citetitle> Wiley, Hoboken, NJ.</para>
          </listitem>
          <listitem id="ch0085s0000li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Kaur R, Shropshire JD, Cross KL, Leigh B, Mansueto AJ, Stewart V, Bordenstein SR, Bordenstein SR.</emphasis> 2021. Living in the endosymbiotic world of <citetitle><emphasis>Wolbachia</emphasis></citetitle>: a centennial review. <citetitle><emphasis>Cell Host Microbe</emphasis></citetitle> <emphasis role="strong">29</emphasis><emphasis role="strong">:</emphasis>879–893.</para>
          </listitem>
          <listitem id="ch0085s0000li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Wass L, Grankvist A, Bell-Sakyi L, Bergström M, Ulfhammer E, Lingblom C, Wennerås C.</emphasis> 2019. Cultivation of the causative agent of human neoehrlichiosis from clinical isolates identifies vascular endothelium as a target of infection. <citetitle><emphasis>Emerg Microbes Infect</emphasis></citetitle> <emphasis role="strong">8</emphasis><emphasis role="strong">:</emphasis>413–425.</para>
          </listitem>
          <listitem id="ch0085s0000li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Brouqui P, Birg ML, Raoult D.</emphasis> 1994. Cytopathic effect, plaque formation, and lysis of <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> grown on continuous cell lines. <citetitle><emphasis>Infect Immun</emphasis></citetitle> <emphasis role="strong">62</emphasis><emphasis role="strong">:</emphasis>405–411.</para>
          </listitem>
          <listitem id="ch0085s0000li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Popov VL, Han VC, Chen SM, Dumler JS, Feng HM, Andreadis TG, Tesh RB, Walker DH.</emphasis> 1998. Ultrastructural differentiation of the genogroups in the genus <citetitle><emphasis>Ehrlichia. J Med Microbiol</emphasis></citetitle> <emphasis role="strong">47</emphasis><emphasis role="strong">:</emphasis>235–251.</para>
          </listitem>
          <listitem id="ch0085s0000li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Dumler JS, Rikihisa Y, Dasch GA.</emphasis> 2015. <citetitle><emphasis>Anaplasma. In</emphasis></citetitle> Whitman WB (ed), <citetitle><emphasis>Bergey’s Manual of Systematics of Archaea and Bacteria.</emphasis></citetitle> Wiley, Hoboken, NJ.</para>
          </listitem>
          <listitem id="ch0085s0000li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Dumler JS, Rikihisa Y, Dasch GA.</emphasis> 2015. <citetitle><emphasis>Ehrlichia. In</emphasis></citetitle> Whitman WB (ed), <citetitle><emphasis>Bergey’s Manual of Systematics of Archaea and Bacteria.</emphasis></citetitle> Wiley, Hoboken, NJ.</para>
          </listitem>
          <listitem id="ch0085s0000li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Ohashi N, Zhi N, Lin Q, Rikihisa Y.</emphasis> 2002. Characterization and transcriptional analysis of gene clusters for a type IV secretion machinery in human granulocytic and monocytic ehrlichiosis agents. <citetitle><emphasis>Infect Immun</emphasis></citetitle> <emphasis role="strong">70:</emphasis>2128–2138.</para>
          </listitem>
          <listitem id="ch0085s0000li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Newton PN, Rolain JM, Rasachak B, Mayxay M, Vathanatham K, Seng P, Phetsouvanh R, Thammavong T, Zahidi J, Suputtamongkol Y, Syhavong B, Raoult D.</emphasis> 2009. <citetitle><emphasis>Sennetsu neorickettsiosis</emphasis></citetitle>: a probable fish-borne cause of fever rediscovered in Laos. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">81</emphasis><emphasis role="strong">:</emphasis>190–194.</para>
          </listitem>
          <listitem id="ch0085s0000li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Taylor MJ, Bandi C, Hoerauf A.</emphasis> 2005. <citetitle><emphasis>Wolbachia</emphasis></citetitle> bacterial endosymbionts of filarial nematodes. <citetitle><emphasis>Adv Parasitol</emphasis></citetitle> <emphasis role="strong">60</emphasis><emphasis role="strong">:</emphasis>245–284.</para>
          </listitem>
          <listitem id="ch0085s0000li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Long SW, Zhang X, Zhang J, Ruble RP, Teel P, Yu XJ.</emphasis> 2003. Evaluation of transovarial transmission and transmissibility of <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> (Rickettsiales: Anaplasmataceae) in <citetitle><emphasis>Amblyomma americanum</emphasis></citetitle> (Acari: Ixodidae). <citetitle><emphasis>J Med Entomol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>1000–1004.</para>
          </listitem>
          <listitem id="ch0085s0000li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Telford SR III, Dawson JE, Katavolos P, Warner CK, Kolbert CP, Persing DH.</emphasis> 1996. Perpetuation of the agent of human granulocytic ehrlichiosis in a deer tick-rodent cycle. <citetitle><emphasis>Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">93:</emphasis>6209–6214.</para>
          </listitem>
          <listitem id="ch0085s0000li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Anderson BE, Sims KG, Olson JG, Childs JE, Piesman JF, Happ CM, Maupin GO, Johnson BJ.</emphasis> 1993. <citetitle><emphasis>Amblyomma americanum</emphasis></citetitle>: a potential vector of human ehrlichiosis. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">49</emphasis><emphasis role="strong">:</emphasis>239–244.</para>
          </listitem>
          <listitem id="ch0085s0000li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Lockhart JM, Davidson WR, Stallknecht DE, Dawson JE, Howerth EW.</emphasis> 1997. Isolation of <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> from wild white-tailed deer (<citetitle><emphasis>Odocoileus virginianus</emphasis></citetitle>) confirms their role as natural reservoir hosts. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">35:</emphasis>1681–1686.</para>
          </listitem>
          <listitem id="ch0085s0000li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Dahlgren FS, Heitman KN, Drexler NA, Massung RF, Behravesh CB.</emphasis> 2015. Human granulocytic anaplasmosis in the United States from 2008 to 2012: a summary of national surveillance data. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">93:</emphasis>66–72.</para>
          </listitem>
          <listitem id="ch0085s0000li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Nichols Heitman K, Dahlgren FS, Drexler NA, Massung RF, Behravesh CB.</emphasis> 2016. Increasing incidence of ehrlichiosis in the United States: a summary of national surveillance of <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> and <citetitle><emphasis>Ehrlichia ewingii</emphasis></citetitle> infections in the United States, 2008-2012. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">94:</emphasis>52–60.</para>
          </listitem>
          <listitem id="ch0085s0000li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 2019. Anaplasmosis. <ulink url="https://www.cdc.gov/anaplasmosis/index.html">https://www.cdc.gov/anaplasmosis/index.html</ulink>. Accessed 5 June 2022.</para>
          </listitem>
          <listitem id="ch0085s0000li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 2019. Ehrlichiosis. <ulink url="https://www.cdc.gov/ehrlichiosis/index.html">https://www.cdc.gov/ehrlichiosis/index.html</ulink>. Accessed 5 June 2022.</para>
          </listitem>
          <listitem id="ch0085s0000li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Bakken JS, Dumler JS.</emphasis> 2015. Human granulocytic anaplasmosis. <citetitle><emphasis>Infect Dis Clin North Am</emphasis></citetitle> <emphasis role="strong">29</emphasis><emphasis role="strong">:</emphasis>341–355.</para>
          </listitem>
          <listitem id="ch0085s0000li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Blanco JR, Oteo JA.</emphasis> 2002. Human granulocytic ehrlichiosis in Europe. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">8</emphasis><emphasis role="strong">:</emphasis>763–772.</para>
          </listitem>
          <listitem id="ch0085s0000li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">European Centre for Disease Prevention and Control.</emphasis> 2022. Human granulocytic anaplasmosis. <ulink url="https://www.ecdc.europa.eu/en/human-granulocytic-anaplasmosis">https://www.ecdc.europa.eu/en/human-granulocytic-anaplasmosis</ulink>. Accessed 5 June 2022.</para>
          </listitem>
          <listitem id="ch0085s0000li0044" role="bibliographyEntry">
            <para>44.<emphasis role="strong">Medlock JM, Hansford KM, Bormane A, Derdakova M, Estrada-Peña A, George JC, Golovljova I, Jaenson TG, Jensen JK, Jensen PM, Kazimirova M, Oteo JA, Papa A, Pfister K, Plantard O, Randolph SE, Rizzoli A, Santos-Silva MM, Sprong H, Vial L, Hendrickx G, Zeller H, Van Bortel W.</emphasis> 2013. Driving forces for changes in geographical distribution of <citetitle><emphasis>Ixodes ricinus</emphasis></citetitle> ticks in Europe. <citetitle><emphasis>Parasit Vectors</emphasis></citetitle> <emphasis role="strong">6:</emphasis>1.</para>
          </listitem>
          <listitem id="ch0085s0000li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Biggs HM, Behravesh CB, Bradley KK, Dahlgren FS, Drexler NA, Dumler JS, Folk SM, Kato CY, Lash RR, Levin ML, Massung RF, Nadelman RB, Nicholson WL, Paddock CD, Pritt BS, Traeger MS.</emphasis> 2016. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis—United States. <citetitle><emphasis>MMWR Recomm Rep</emphasis></citetitle> <emphasis role="strong">65:</emphasis>1–44.</para>
          </listitem>
          <listitem id="ch0085s0000li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Jiang JF, Jiang BG, Yu JH, Zhang WY, Gao HW, Zhan L, Sun Y, Zhang XA, Zhang PH, Liu W, Wu XM, Xu RM, Cao WC.</emphasis> 2011. <citetitle><emphasis>Anaplasma phagocytophilum</emphasis></citetitle> infection in ticks, China-Russia border. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">17</emphasis><emphasis role="strong">:</emphasis>932–934.</para>
          </listitem>
          <listitem id="ch0085s0000li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Townsend RL, Moritz ED, Fialkow LB, Berardi V, Stramer SL.</emphasis> 2014. Probable transfusion-transmission of <citetitle><emphasis>Anaplasma phagocytophilum</emphasis></citetitle> by leukoreduced platelets. <citetitle><emphasis>Transfusion</emphasis></citetitle> <emphasis role="strong">54:</emphasis>2828–2832.</para>
          </listitem>
          <listitem id="ch0085s0000li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Mowla SJ, Drexler NA, Cherry CC, Annambholta PD, Kracalik IT, Basavaraju SV.</emphasis> 2021. Ehrlichiosis and anaplasmosis among transfusion and transplant recipients in the United States. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">27:</emphasis>2768–2775.</para>
          </listitem>
          <listitem id="ch0085s0000li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Horowitz HW, Kilchevsky E, Haber S, Aguero-Rosenfeld M, Kranwinkel R, James EK, Wong SJ, Chu F, Liveris D, Schwartz I.</emphasis> 1998. Perinatal transmission of the agent of human granulocytic ehrlichiosis. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">339</emphasis><emphasis role="strong">:</emphasis>375–378.</para>
          </listitem>
          <listitem id="ch0085s0000li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Petrovec M, Lotric Furlan S, Zupanc TA, Strle F, Brouqui P, Roux V, Dumler JS.</emphasis> 1997. Human disease in Europe caused by a granulocytic <citetitle><emphasis>Ehrlichia</emphasis></citetitle> species. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">35:</emphasis>1556–1559.</para>
          </listitem>
          <listitem id="ch0085s0000li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 2019. Rocky Mountain Spotted Fever (RMSF). <ulink url="https://www.cdc.gov/rmsf/index.html">https://www.cdc.gov/rmsf/index.html</ulink>. Accessed 5 June 2022.</para>
          </listitem>
          <listitem id="ch0085s0000li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Bakken JS, Goellner P, Van Etten M, Boyle DZ, Swonger OL, Mattson S, Krueth J, Tilden RL, Asanovich K, Walls J, Dumler JS.</emphasis> 1998. Seroprevalence of human granulocytic ehrlichiosis among permanent residents of northwestern Wisconsin. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">27:</emphasis>1491–1496.</para>
          </listitem>
          <listitem id="ch0085s0000li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Aguero-Rosenfeld ME, Donnarumma L, Zentmaier L, Jacob J, Frey M, Noto R, Carbonaro CA, Wormser GP.</emphasis> 2002. Seroprevalence of antibodies that react with <citetitle><emphasis>Anaplasma phagocytophila</emphasis></citetitle>, the agent of human granulocytic ehrlichiosis, in different populations in Westchester County, New York. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>2612–2615.</para>
          </listitem>
          <listitem id="ch0085s0000li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Leiby DA, Chung AP, Cable RG, Trouern-Trend J, McCullough J, Homer MJ, Reynolds LD, Houghton RL, Lodes MJ, Persing DH.</emphasis> 2002. Relationship between tick bites and the seroprevalence of <citetitle><emphasis>Babesia microti</emphasis></citetitle> and <citetitle><emphasis>Anaplasma phagocytophila</emphasis></citetitle> (previously <citetitle><emphasis>Ehrlichia</emphasis></citetitle> sp.) in blood donors. <citetitle><emphasis>Transfusion</emphasis></citetitle> <emphasis role="strong">42:</emphasis>1585–1591.</para>
          </listitem>
          <listitem id="ch0085s0000li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Kadkhoda K, Gretchen A.</emphasis> 2016. Retrospective study investigating the seroprevalence of <citetitle><emphasis>Anaplasma phagocytophilum</emphasis></citetitle> in Manitoba, Canada: 2011-2014. <citetitle><emphasis>Open Forum Infect Dis</emphasis></citetitle> <emphasis role="strong">3:</emphasis>ofw199.</para>
          </listitem>
          <listitem id="ch0085s0000li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Little S, Braff J, Place J, Buch J, Dewage BG, Knupp A, Beall M.</emphasis> 2021. Canine infection with <citetitle><emphasis>Dirofilaria immitis</emphasis></citetitle>, <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle>, <citetitle><emphasis>Anaplasma</emphasis></citetitle> spp., and <citetitle><emphasis>Ehrlichia</emphasis></citetitle> spp. in the United States, 2013-2019. <citetitle><emphasis>Parasit Vectors</emphasis></citetitle> <emphasis role="strong">14:</emphasis>10.</para>
          </listitem>
          <listitem id="ch0085s0000li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Morissette E, Massung RF, Foley JE, Alleman AR, Foley P, Barbet AF.</emphasis> 2009. Diversity of <citetitle><emphasis>Anaplasma phagocytophilum</emphasis></citetitle> strains, USA. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">15</emphasis><emphasis role="strong">:</emphasis>928–931.</para>
          </listitem>
          <listitem id="ch0085s0000li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Stafford KC III, Massung RF, Magnarelli LA, Ijdo JW, Anderson JF.</emphasis> 1999. Infection with agents of human granulocytic ehrlichiosis, Lyme disease, and babesiosis in wild white-footed mice (<citetitle><emphasis>Peromyscus leucopus</emphasis></citetitle>) in Connecticut. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>2887–2892.</para>
          </listitem>
          <listitem id="ch0085s0000li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Li H, Jiang JF, Liu W, Zheng YC, Huo QB, Tang K, Zuo SY, Liu K, Jiang BG, Yang H, Cao WC.</emphasis> 2012. Human infection with <citetitle><emphasis>Candidatus</emphasis></citetitle> Neoehrlichia mikurensis, China. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">18:</emphasis>1636–1639.</para>
          </listitem>
          <listitem id="ch0085s0000li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Chochlakis D, Ioannou I, Tselentis Y, Psaroulaki A.</emphasis> 2010. Human anaplasmosis and <citetitle><emphasis>Anaplasma ovis</emphasis></citetitle> variant. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">16:</emphasis>1031–1032.</para>
          </listitem>
          <listitem id="ch0085s0000li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Reeves WK, Loftis AD, Nicholson WL, Czarkowski AG.</emphasis> 2008. The first report of human illness associated with the Panola Mountain <citetitle><emphasis>Ehrlichia</emphasis></citetitle> species: a case report. <citetitle><emphasis>J Med Case Reports</emphasis></citetitle> <emphasis role="strong">2:</emphasis>139.</para>
          </listitem>
          <listitem id="ch0085s0000li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Unver A, Perez M, Orellana N, Huang H, Rikihisa Y.</emphasis> 2001. Molecular and antigenic comparison of <citetitle><emphasis>Ehrlichia canis</emphasis></citetitle> isolates from dogs, ticks, and a human in Venezuela. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>2788–2793.</para>
          </listitem>
          <listitem id="ch0085s0000li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Pritt BS, Sloan LM, Johnson DK, Munderloh UG, Paskewitz SM, McElroy KM, McFadden JD, Binnicker MJ, Neitzel DF, Liu G, Nicholson WL, Nelson CM, Franson JJ, Martin SA, Cunningham SA, Steward CR, Bogumill K, Bjorgaard ME, Davis JP, McQuiston JH, Warshauer DM, Wilhelm MP, Patel R, Trivedi VA, Eremeeva ME.</emphasis> 2011. Emergence of a new pathogenic <citetitle><emphasis>Ehrlichia</emphasis></citetitle> species, Wisconsin and Minnesota, 2009. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">365</emphasis><emphasis role="strong">:</emphasis>422–429.</para>
          </listitem>
          <listitem id="ch0085s0000li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Regan J, Matthias J, Green-Murphy A, Stanek D, Bertholf M, Pritt BS, Sloan LM, Kelly AJ, Singleton J, McQuiston JH, Hocevar SN, Whittle JP.</emphasis> 2013. A confirmed <citetitle><emphasis>Ehrlichia ewingii</emphasis></citetitle> infection likely acquired through platelet transfusion. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">56:</emphasis>e105–e107.</para>
          </listitem>
          <listitem id="ch0085s0000li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Antony SJ, Dummer JS, Hunter E.</emphasis> 1995. Human ehrlichiosis in a liver transplant recipient. <citetitle><emphasis>Transplantation</emphasis></citetitle> <emphasis role="strong">60</emphasis><emphasis role="strong">:</emphasis>879–881.</para>
          </listitem>
          <listitem id="ch0085s0000li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">Sachdev SH, Joshi V, Cox ER, Amoroso A, Palekar S.</emphasis> 2014. Severe life-threatening <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> infections transmitted through solid organ transplantation. <citetitle><emphasis>Transpl Infect Dis</emphasis></citetitle> <emphasis role="strong">16</emphasis><emphasis role="strong">:</emphasis>119–124.</para>
          </listitem>
          <listitem id="ch0085s0000li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Buller RS, Arens M, Hmiel SP, Paddock CD, Sumner JW, Rikhisa Y, Unver A, Gaudreault-Keener M, Manian FA, Liddell AM, Schmulewitz N, Storch GA.</emphasis> 1999. <citetitle><emphasis>Ehrlichia ewingii</emphasis></citetitle>, a newly recognized agent of human ehrlichiosis. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">341</emphasis><emphasis role="strong">:</emphasis>148–155.</para>
          </listitem>
          <listitem id="ch0085s0000li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Dawson JE, Anderson BE, Fishbein DB, Sanchez JL, Goldsmith CS, Wilson KH, Duntley CW.</emphasis> 1991. Isolation and characterization of an <citetitle><emphasis>Ehrlichia</emphasis></citetitle> sp. from a patient diagnosed with human ehrlichiosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">29:</emphasis>2741–2745.</para>
          </listitem>
          <listitem id="ch0085s0000li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Pritt BS, Allerdice MEJ, Sloan LM, Paddock CD, Munderloh UG, Rikihisa Y, Tajima T, Paskewitz SM, Neitzel DF, Hoang Johnson DK, Schiffman E, Davis JP, Goldsmith CS, Nelson CM, Karpathy SE.</emphasis> 2017. Proposal to reclassify <citetitle><emphasis>Ehrlichia muris</emphasis></citetitle> as <citetitle><emphasis>Ehrlichia muris</emphasis></citetitle> subsp. <citetitle><emphasis>muris</emphasis></citetitle> subsp. nov. and description of <citetitle><emphasis>Ehrlichia muris</emphasis></citetitle> subsp. <citetitle><emphasis>eauclairensis</emphasis></citetitle> subsp. nov., a newly recognized tick-borne pathogen of humans. <citetitle><emphasis>Int J Syst Evol Microbiol</emphasis></citetitle> <emphasis role="strong">67:</emphasis>2121–2126.</para>
          </listitem>
          <listitem id="ch0085s0000li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Johnson DK, Schiffman EK, Davis JP, Neitzel DF, Sloan LM, Nicholson WL, Fritsche TR, Steward CR, Ray JA, Miller TK, Feist MA, Uphoff TS, Franson JJ, Livermore AL, Deedon AK, Theel ES, Pritt BS.</emphasis> 2015. Human infection with <citetitle><emphasis>Ehrlichia muris</emphasis></citetitle>-like pathogen, United States, 2007-2013. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">21:</emphasis>1794–1799.</para>
          </listitem>
          <listitem id="ch0085s0000li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Stromdahl E, Hamer S, Jenkins S, Sloan L, Williamson P, Foster E, Nadolny R, Elkins C, Vince M, Pritt B.</emphasis> 2014. Comparison of phenology and pathogen prevalence, including infection with the <citetitle><emphasis>Ehrlichia muris</emphasis></citetitle>-like (EML) agent, of <citetitle><emphasis>Ixodes scapularis</emphasis></citetitle> removed from soldiers in the midwestern and the northeastern United States over a 15 year period (1997-2012). <citetitle><emphasis>Parasit Vectors</emphasis></citetitle> <emphasis role="strong">7:</emphasis>553.</para>
          </listitem>
          <listitem id="ch0085s0000li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Fleshman AC, Foster E, Maes SE, Eisen RJ.</emphasis> Reported county-level distribution of seven human pathogens detected in host-seeking <citetitle><emphasis>Ixodes scapularis</emphasis></citetitle> and <citetitle><emphasis>Ixodes pacifus</emphasis></citetitle> (Acari: Ixodidae) in the contiguous United States. <citetitle><emphasis>J Med Entomol</emphasis></citetitle>, in press.</para>
          </listitem>
          <listitem id="ch0085s0000li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Xu G, Pearson P, Rich SM.</emphasis> 2018. <citetitle><emphasis>Ehrlichia muris</emphasis></citetitle> in <citetitle><emphasis>Ixodes cookei</emphasis></citetitle> ticks, northeastern United States, 2016-2017. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">24:</emphasis>1143–1144.</para>
          </listitem>
          <listitem id="ch0085s0000li0074" role="bibliographyEntry">
            <para>74.<emphasis role="strong">Kingry L, Sheldon S, Oatman S, Pritt B, Anacker M, Bjork J, Neitzel D, Strain A, Berry J, Sloan L, Respicio-Kingry L, Dietrich E, Bloch K, Moncayo A, Srinivasamoorthy G, Hu B, Hinckley A, Mead P, Kugeler K, Petersen J.</emphasis> 2020. Targeted metagenomics for clinical detection and discovery of bacterial tick-borne pathogens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>e00147-20.</para>
          </listitem>
          <listitem id="ch0085s0000li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Christenson M, Lee X, Larson S, Johnson DH, Jensen J, Meller M, Paskewitz S.</emphasis> 2017. Occurrence of <citetitle><emphasis>Amblyomma americanum</emphasis></citetitle> (Acari: Ixodidae) and human infection with <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> in Wisconsin, 2008-2015. <citetitle><emphasis>J Med Entomol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>752–756.</para>
          </listitem>
          <listitem id="ch0085s0000li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Harris RM, Couturier BA, Sample SC, Coulter KS, Casey KK, Schlaberg R.</emphasis> 2016. Expanded geographic distribution and clinical characteristics of <citetitle><emphasis>Ehrlichia ewingii</emphasis></citetitle> infections, United States. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">22</emphasis><emphasis role="strong">:</emphasis>862–865.</para>
          </listitem>
          <listitem id="ch0085s0000li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Fishbein DB, Dawson JE, Robinson LE.</emphasis> 1994. Human ehrlichiosis in the United States, 1985 to 1990. <citetitle><emphasis>Ann Intern Med</emphasis></citetitle> <emphasis role="strong">120</emphasis><emphasis role="strong">:</emphasis>736–743.</para>
          </listitem>
          <listitem id="ch0085s0000li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Marshall GS, Jacobs RF, Schutze GE, Paxton H, Buckingham SC, DeVincenzo JP, Jackson MA, San Joaquin VH, Standaert SM, Woods CR, Tick-Borne Infections in Children Study Group.</emphasis> 2002. <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> seroprevalence among children in the southeast and south-central regions of the United States. <citetitle><emphasis>Arch Pediatr Adolesc Med</emphasis></citetitle> <emphasis role="strong">156</emphasis><emphasis role="strong">:</emphasis>166–170.</para>
          </listitem>
          <listitem id="ch0085s0000li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">Yabsley MJ, Varela AS, Tate CM, Dugan VG, Stallknecht DE, Little SE, Davidson WR.</emphasis> 2002. <citetitle><emphasis>Ehrlichia ewingii</emphasis></citetitle> infection in white-tailed deer (<citetitle><emphasis>Odocoileus virginianus</emphasis></citetitle>). <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">8</emphasis><emphasis role="strong">:</emphasis>668–671.</para>
          </listitem>
          <listitem id="ch0085s0000li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">Arens MQ, Liddell AM, Buening G, Gaudreault-Keener M, Sumner JW, Comer JA, Buller RS, Storch GA.</emphasis> 2003. Detection of <citetitle><emphasis>Ehrlichia</emphasis></citetitle> spp. in the blood of wild white-tailed deer in Missouri by PCR assay and serologic analysis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>1263–1265.</para>
          </listitem>
          <listitem id="ch0085s0000li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">Dawson JE, Ewing SA.</emphasis> 1992. Susceptibility of dogs to infection with <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle>, causative agent of human ehrlichiosis. <citetitle><emphasis>Am J Vet Res</emphasis></citetitle> <emphasis role="strong">53:</emphasis>1322–1327.</para>
          </listitem>
          <listitem id="ch0085s0000li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Childs JE, Paddock CD.</emphasis> 2003. The ascendancy of <citetitle><emphasis>Amblyomma americanum</emphasis></citetitle> as a vector of pathogens affecting humans in the United States. <citetitle><emphasis>Annu Rev Entomol</emphasis></citetitle> <emphasis role="strong">48</emphasis><emphasis role="strong">:</emphasis>307–337.</para>
          </listitem>
          <listitem id="ch0085s0000li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">Lynn GE, Oliver JD, Cornax I, O’Sullivan MG, Munderloh UG.</emphasis> 2017. Experimental evaluation of <citetitle><emphasis>Peromyscus leucopus</emphasis></citetitle> as a reservoir host of the <citetitle><emphasis>Ehrlichia muris</emphasis></citetitle>-like agent. <citetitle><emphasis>Parasit Vectors</emphasis></citetitle> <emphasis role="strong">10:</emphasis>48.</para>
          </listitem>
          <listitem id="ch0085s0000li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Castillo CG, Eremeeva ME, Paskewitz SM, Sloan LM, Lee X, Irwin WE, Tonsberg S, Pritt BS.</emphasis> 2015. Detection of human pathogenic <citetitle><emphasis>Ehrlichia muris</emphasis></citetitle>-like agent in <citetitle><emphasis>Peromyscus leucopus. Ticks Tick Borne Dis</emphasis></citetitle> <emphasis role="strong">6</emphasis><emphasis role="strong">:</emphasis>155–157.</para>
          </listitem>
          <listitem id="ch0085s0000li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Misao T, Kobayashi Y.</emphasis> 1955. Studies on infectious mononucleosis (glandular fever). I. Isolation of etiologic agent from blood, bone marrow, and lymph node of a patient with infectious mononucleosis by using mice. <citetitle><emphasis>Kyushu J Med Sci</emphasis></citetitle> <emphasis role="strong">6:</emphasis>145–152.</para>
          </listitem>
          <listitem id="ch0085s0000li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Bhengsri S, Baggett HC, Edouard S, Dowell SF, Dasch GA, Fisk TL, Raoult D, Parola P.</emphasis> 2016. Sennetsu neorickettsiosis, spotted fever group, and typhus group rickettsioses in three provinces in Thailand. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">95:</emphasis>43–49.</para>
          </listitem>
          <listitem id="ch0085s0000li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">McNulty SN, Tort JF, Rinaldi G, Fischer K, Rosa BA, Smircich P, Fontenla S, Choi YJ, Tyagi R, Hallsworth-Pepin K, Mann VH, Kammili L, Latham PS, Dell’Oca N, Dominguez F, Carmona C, Fischer PU, Brindley PJ, Mitreva M.</emphasis> 2017. Genomes of <citetitle><emphasis>Fasciola hepatica</emphasis></citetitle> from the Americas reveal colonization with <citetitle><emphasis>Neorickettsia</emphasis></citetitle> endobacteria related to the agents of Potomac horse and human sennetsu fevers. <citetitle><emphasis>PLoS Genet</emphasis></citetitle> <emphasis role="strong">13:</emphasis>e1006537.</para>
          </listitem>
          <listitem id="ch0085s0000li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Dittrich S, Phuklia W, Turner GD, Rattanavong S, Chansamouth V, Dumler SJ, Ferguson DJ, Paris DH, Newton PN.</emphasis> 2015. <citetitle><emphasis>Neorickettsia sennetsu</emphasis></citetitle> as a neglected cause of fever in South-East Asia. <citetitle><emphasis>PLoS Negl Trop Dis</emphasis></citetitle> <emphasis role="strong">9:</emphasis>e0003908.</para>
          </listitem>
          <listitem id="ch0085s0000li0089" role="bibliographyEntry">
            <anchor id="ch0085s0000a0063"/>
            <para>89.<emphasis role="strong">Wennerås C.</emphasis> 2015. Infections with the tick-borne bacterium <citetitle><emphasis>Candidatus</emphasis></citetitle> Neoehrlichia mikurensis. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">21</emphasis><emphasis role="strong">:</emphasis>621–630.</para>
          </listitem>
          <listitem id="ch0085s0000li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Portillo A, Santibáñez P, Palomar AM, Santibáñez S, Oteo JA.</emphasis> 2018. ‘<citetitle><emphasis>Candidatus</emphasis></citetitle> Neoehrlichia mikurensis’ in Europe. <citetitle><emphasis>New Microbes New Infect</emphasis></citetitle> <emphasis role="strong">22:</emphasis>30–36.</para>
          </listitem>
          <listitem id="ch0085s0000li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Höper L, Skoog E, Stenson M, Grankvist A, Wass L, Olsen B, Nilsson K, Mårtensson A, Söderlind J, Sakinis A, Wennerås C.</emphasis> 2021. Vasculitis due to <citetitle><emphasis>Candidatus</emphasis></citetitle> Neoehrlichia mikurensis: a cohort study of 40 Swedish patients. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">73:</emphasis>e2372–e2378.</para>
          </listitem>
          <listitem id="ch0085s0000li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Hongo I, Bloch KC.</emphasis> 2006. <citetitle><emphasis>Ehrlichia</emphasis></citetitle> infection of the central nervous system. <citetitle><emphasis>Curr Treat Options Neurol</emphasis></citetitle> <emphasis role="strong">8</emphasis><emphasis role="strong">:</emphasis>179–184.</para>
          </listitem>
          <listitem id="ch0085s0000li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Dumler JS, Barat NC, Barat CE, Bakken JS.</emphasis> 2007. Human granulocytic anaplasmosis and macrophage activation. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">45</emphasis><emphasis role="strong">:</emphasis>199–204.</para>
          </listitem>
          <listitem id="ch0085s0000li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Bakken JS, Aguero-Rosenfeld ME, Tilden RL, Wormser GP, Horowitz HW, Raffalli JT, Baluch M, Riddell D, Walls JJ, Dumler JS.</emphasis> 2001. Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">32</emphasis><emphasis role="strong">:</emphasis>862–870.</para>
          </listitem>
          <listitem id="ch0085s0000li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Hossain D, Aguero-Rosenfeld ME, Horowitz HW, Wu JM, Hsieh TC, Sachdeva N, Peterson SJ, Dumler JS, Wormser GP.</emphasis> 1999. Clinical and laboratory evolution of a culture-confirmed case of human granulocytic ehrlichiosis. <citetitle><emphasis>Conn Med</emphasis></citetitle> <emphasis role="strong">63:</emphasis>265–270.</para>
          </listitem>
          <listitem id="ch0085s0000li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">Lotrič-Furlan S, Rojko T, Jelovšek M, Petrovec M, Avšič-Županc T, Lusa L, Strle F.</emphasis> 2015. Comparison of clinical and laboratory characteristics of patients fulfilling criteria for proven and probable human granulocytic anaplasmosis. <citetitle><emphasis>Microbes Infect</emphasis></citetitle> <emphasis role="strong">17</emphasis><emphasis role="strong">:</emphasis>829–833.</para>
          </listitem>
          <listitem id="ch0085s0000li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">Schotthoefer AM, Schrodi SJ, Meece JK, Fritsche TR, Shukla SK.</emphasis> 2017. Pro-inflammatory immune responses are associated with clinical signs and symptoms of human anaplasmosis. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">12:</emphasis>e0179655.</para>
          </listitem>
          <listitem id="ch0085s0000li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Bakken JS, Dumler JS.</emphasis> 2000. Human granulocytic ehrlichiosis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">31</emphasis><emphasis role="strong">:</emphasis>554–560.</para>
          </listitem>
          <listitem id="ch0085s0000li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Dumler JS, Madigan JE, Pusterla N, Bakken JS.</emphasis> 2007. Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">45</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S45–S51.</para>
          </listitem>
          <listitem id="ch0085s0000li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Zhang L, Wang G, Liu Q, Chen C, Li J, Long B, Yu H, Zhang Z, He J, Qu Z, Yu J, Liu Y, Dong T, Yao N, Wang Y, Cheng X, Xu J.</emphasis> 2013. Molecular analysis of <citetitle><emphasis>Anaplasma phagocytophilum</emphasis></citetitle> isolated from patients with febrile diseases of unknown etiology in China. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e57155.</para>
          </listitem>
          <listitem id="ch0085s0000li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Liu Y, Yu XJ.</emphasis> 2016. Human granulocytic anaplasmosis and Lyme disease—reply. <citetitle><emphasis>JAMA</emphasis></citetitle> <emphasis role="strong">316:</emphasis>99.</para>
          </listitem>
          <listitem id="ch0085s0000li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Paddock CD, Childs JE.</emphasis> 2003. <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle>: a prototypical emerging pathogen. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">16:</emphasis>37–64.</para>
          </listitem>
          <listitem id="ch0085s0000li0103" role="bibliographyEntry">
            <para>103.<emphasis role="strong">Schutze GE, Buckingham SC, Marshall GS, Woods CR, Jackson MA, Patterson LE, Jacobs RF, Tick-borne Infections in Children Study (TICS) Group.</emphasis> 2007. Human monocytic ehrlichiosis in children. <citetitle><emphasis>Pediatr Infect Dis J</emphasis></citetitle> <emphasis role="strong">26</emphasis><emphasis role="strong">:</emphasis>475–479.</para>
          </listitem>
          <listitem id="ch0085s0000li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Standaert SM, Yu T, Scott MA, Childs JE, Paddock CD, Nicholson WL, Singleton J Jr, Blaser MJ.</emphasis> 2000. Primary isolation of <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> from patients with febrile illnesses: clinical and molecular characteristics. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">181:</emphasis>1082–1088.</para>
          </listitem>
          <listitem id="ch0085s0000li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Pandey R, Kochar R, Kemp S, Rotaru D, Shah SV.</emphasis> 2013. Ehrlichiosis presenting with toxic shock-like syndrome and secondary hemophagocytic lymphohistiocytosis. <citetitle><emphasis>J Ark Med Soc</emphasis></citetitle> <emphasis role="strong">109:</emphasis>280–282.</para>
          </listitem>
          <listitem id="ch0085s0000li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Hanson D, Walter AW, Powell J.</emphasis> 2011. <citetitle><emphasis>Ehrlichia</emphasis></citetitle>-induced hemophagocytic lymphohistiocytosis in two children. <citetitle><emphasis>Pediatr Blood Cancer</emphasis></citetitle> <emphasis role="strong">56</emphasis><emphasis role="strong">:</emphasis>661–663.</para>
          </listitem>
          <listitem id="ch0085s0000li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Paddock CD, Sumner JW, Shore GM, Bartley DC, Elie RC, McQuade JG, Martin CR, Goldsmith CS, Childs JE.</emphasis> 1997. Isolation and characterization of <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> strains from patients with fatal ehrlichiosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">35:</emphasis>2496–2502.</para>
          </listitem>
          <listitem id="ch0085s0000li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Paddock CD, Folk SM, Shore GM, Machado LJ, Huycke MM, Slater LN, Liddell AM, Buller RS, Storch GA, Monson TP, Rimland D, Sumner JW, Singleton J, Bloch KC, Tang YW, Standaert SM, Childs JE.</emphasis> 2001. Infections with <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> and <citetitle><emphasis>Ehrlichia ewingii</emphasis></citetitle> in persons coinfected with human immunodeficiency virus. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">33:</emphasis>1586–1594.</para>
          </listitem>
          <listitem id="ch0085s0000li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Safdar N, Love RB, Maki DG.</emphasis> 2002. Severe <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> infection in a lung transplant recipient: a review of ehrlichiosis in the immunocompromised patient. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">8</emphasis><emphasis role="strong">:</emphasis>320–323.</para>
          </listitem>
          <listitem id="ch0085s0000li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Stone JH, Dierberg K, Aram G, Dumler JS.</emphasis> 2004. Human monocytic ehrlichiosis. <citetitle><emphasis>JAMA</emphasis></citetitle> <emphasis role="strong">292:</emphasis>2263–2270.</para>
          </listitem>
          <listitem id="ch0085s0000li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">Demma LJ, Holman RC, McQuiston JH, Krebs JW, Swerdlow DL.</emphasis> 2005. Epidemiology of human ehrlichiosis and anaplasmosis in the United States, 2001-2002. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">73</emphasis><emphasis role="strong">:</emphasis>400–409.</para>
          </listitem>
          <listitem id="ch0085s0000li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">Hamburg BJ, Storch GA, Micek ST, Kollef MH.</emphasis> 2008. The importance of early treatment with doxycycline in human ehrlichiosis. <citetitle><emphasis>Medicine (Baltimore)</emphasis></citetitle> <emphasis role="strong">87:</emphasis>53–60.</para>
          </listitem>
          <listitem id="ch0085s0000li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Chen XP, Dong YJ, Guo WP, Wang W, Li MH, Xu J, Dumler JS, Zhang YZ.</emphasis> 2015. Detection of <citetitle><emphasis>Wolbachia</emphasis></citetitle> genes in a patient with non-Hodgkin’s lymphoma. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">21:</emphasis>182.e1–182.e4.</para>
          </listitem>
          <listitem id="ch0085s0000li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Turner JD, Langley RS, Johnston KL, Gentil K, Ford L, Wu B, Graham M, Sharpley F, Slatko B, Pearlman E, Taylor MJ.</emphasis> 2009. <citetitle><emphasis>Wolbachia</emphasis></citetitle> lipoprotein stimulates innate and adaptive immunity through Toll-like receptors 2 and 6 to induce disease manifestations of filariasis. <citetitle><emphasis>J Biol Chem</emphasis></citetitle> <emphasis role="strong">284:</emphasis>22364–22378.</para>
          </listitem>
          <listitem id="ch0085s0000li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 2018. Tickborne diseases of the United States. A Reference Manual for Healthcare Providers, 5th ed. <ulink url="https://www.cdc.gov/ticks/tickbornediseases/TickborneDiseases-P.pdf">https://www.cdc.gov/ticks/tickbornediseases/TickborneDiseases-P.pdf</ulink>. Accessed 15 May 2022.</para>
          </listitem>
          <listitem id="ch0085s0000li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gilligan PH, Gonzalez MD, Jerris RC, Kehl SC, Patel R, Pritt BS, Richter SS, Robinson-Dunn B, Schwartzman JD, Snyder JW, Telford S III, Theel ES, Thomson RB Jr, Weinstein MP, Yao JD.</emphasis> 2018. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">67:</emphasis>e1–e94.</para>
          </listitem>
          <listitem id="ch0085s0000li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Olano JP, Hogrefe W, Seaton B, Walker DH.</emphasis> 2003. Clinical manifestations, epidemiology, and laboratory diagnosis of human monocytotropic ehrlichiosis in a commercial laboratory setting. <citetitle><emphasis>Clin Diagn Lab Immunol</emphasis></citetitle> <emphasis role="strong">10:</emphasis>891–896.</para>
          </listitem>
          <listitem id="ch0085s0000li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Goodman JL, Nelson C, Vitale B, Madigan JE, Dumler JS, Kurtti TJ, Munderloh UG.</emphasis> 1996. Direct cultivation of the causative agent of human granulocytic ehrlichiosis. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">334</emphasis><emphasis role="strong">:</emphasis>209–215.</para>
          </listitem>
          <listitem id="ch0085s0000li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Kalantarpour F, Chowdhury I, Wormser GP, Aguero-Rosenfeld ME.</emphasis> 2000. Survival of the human granulocytic ehrlichiosis agent under refrigeration conditions. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>2398–2399.</para>
          </listitem>
          <listitem id="ch0085s0000li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Carlyon JA.</emphasis> 2005. Laboratory maintenance of <citetitle><emphasis>Anaplasma phagocytophilum</emphasis></citetitle>. <citetitle><emphasis>Curr Protoc Microbiol</emphasis></citetitle> Chapter 3:Unit 3A.2.</para>
          </listitem>
          <listitem id="ch0085s0000li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Cheng C, Ganta RR.</emphasis> 2008. Laboratory maintenance of Ehrlichia chaffeensis and Ehrlichia canis and recovery of organisms for molecular biology and proteomics studies. <citetitle><emphasis>Curr Protoc Microbiol</emphasis></citetitle> Chapter 3:Unit 3A.1.</para>
          </listitem>
          <listitem id="ch0085s0000li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">Dixon DM, Branda JA, Clark SH, Dumler JS, Horowitz HW, Perdue SS, Pritt BS, Sexton DJ, Storch GA, Walker DH.</emphasis> 2021. Ehrlichiosis and anaplasmosis subcommittee report to the Tick-borne Disease Working Group. <citetitle><emphasis>Ticks Tick Borne Dis</emphasis></citetitle> <emphasis role="strong">12:</emphasis>101823.</para>
          </listitem>
          <listitem id="ch0085s0000li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Schotthoefer AM, Meece JK, Ivacic LC, Bertz PD, Zhang K, Weiler T, Uphoff TS, Fritsche TR.</emphasis> 2013. Comparison of a real-time PCR method with serology and blood smear analysis for diagnosis of human anaplasmosis: importance of infection time course for optimal test utilization. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>2147–2153.</para>
          </listitem>
          <listitem id="ch0085s0000li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Dumler JS, Dawson JE, Walker DH.</emphasis> 1993. Human ehrlichiosis: hematopathology and immunohistologic detection of <citetitle><emphasis>Ehrlichia chaffeensis. Hum Pathol</emphasis></citetitle> <emphasis role="strong">24</emphasis><emphasis role="strong">:</emphasis>391–396.</para>
          </listitem>
          <listitem id="ch0085s0000li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">Hamilton KS, Standaert SM, Kinney MC.</emphasis> 2004. Characteristic peripheral blood findings in human ehrlichiosis. <citetitle><emphasis>Mod Pathol</emphasis></citetitle> <emphasis role="strong">17</emphasis><emphasis role="strong">:</emphasis>512–517.</para>
          </listitem>
          <listitem id="ch0085s0000li0126" role="bibliographyEntry">
            <anchor id="ch0085s0000a0064"/>
            <para>126.<emphasis role="strong">Aguero-Rosenfeld ME.</emphasis> 2002. Diagnosis of human granulocytic ehrlichiosis: state of the art. <citetitle><emphasis>Vector Borne Zoonotic Dis</emphasis></citetitle> <emphasis role="strong">2</emphasis><emphasis role="strong">:</emphasis>233–239.</para>
          </listitem>
          <listitem id="ch0085s0000li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Rand JV, Tarasen AJ, Kumar J, Homan SM, Tobin E.</emphasis> 2014. Intracytoplasmic granulocytic morulae counts on confirmed cases of ehrlichiosis/anaplasmosis in the Northeast. <citetitle><emphasis>Am J Clin Pathol</emphasis></citetitle> <emphasis role="strong">141</emphasis><emphasis role="strong">:</emphasis>683–686.</para>
          </listitem>
          <listitem id="ch0085s0000li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Bakken JS, Dumler JS, Chen SM, Eckman MR, Van Etta LL, Walker DH.</emphasis> 1994. Human granulocytic ehrlichiosis in the upper Midwest United States. A new species emerging? <citetitle><emphasis>JAMA</emphasis></citetitle> <emphasis role="strong">272</emphasis><emphasis role="strong">:</emphasis>212–218.</para>
          </listitem>
          <listitem id="ch0085s0000li0129" role="bibliographyEntry">
            <para>129.<emphasis role="strong">Aguero-Rosenfeld ME, Horowitz HW, Wormser GP, McKenna DF, Nowakowski J, Muñoz J, Dumler JS.</emphasis> 1996. Human granulocytic ehrlichiosis: a case series from a medical center in New York State. <citetitle><emphasis>Ann Intern Med</emphasis></citetitle> <emphasis role="strong">125</emphasis><emphasis role="strong">:</emphasis>904–908.</para>
          </listitem>
          <listitem id="ch0085s0000li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Lepidi H, Bunnell JE, Martin ME, Madigan JE, Stuen S, Dumler JS.</emphasis> 2000. Comparative pathology, and immunohistology associated with clinical illness after <citetitle><emphasis>Ehrlichia phagocytophila</emphasis></citetitle>-group infections. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">62:</emphasis>29–37.</para>
          </listitem>
          <listitem id="ch0085s0000li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Dunn BE, Monson TP, Dumler JS, Morris CC, Westbrook AB, Duncan JL, Dawson JE, Sims KG, Anderson BE.</emphasis> 1992. Identification of <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> morulae in cerebrospinal fluid mononuclear cells. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">30:</emphasis>2207–2210.</para>
          </listitem>
          <listitem id="ch0085s0000li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Yu X, Brouqui P, Dumler JS, Raoult D.</emphasis> 1993. Detection of <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> in human tissue by using a species-specific monoclonal antibody. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">31:</emphasis>3284–3288.</para>
          </listitem>
          <listitem id="ch0085s0000li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Sirigireddy KR, Ganta RR.</emphasis> 2005. Multiplex detection of <citetitle><emphasis>Ehrlichia</emphasis></citetitle> and <citetitle><emphasis>Anaplasma</emphasis></citetitle> species pathogens in peripheral blood by real-time reverse transcriptase-polymerase chain reaction. <citetitle><emphasis>J Mol Diagn</emphasis></citetitle> <emphasis role="strong">7</emphasis><emphasis role="strong">:</emphasis>308–316.</para>
          </listitem>
          <listitem id="ch0085s0000li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Edelman DC, Dumler JS.</emphasis> 1996. Evaluation of an improved PCR diagnostic assay for human granulocytic ehrlichiosis. <citetitle><emphasis>Mol Diagn</emphasis></citetitle> <emphasis role="strong">1:</emphasis>41–49.</para>
          </listitem>
          <listitem id="ch0085s0000li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Massung RF, Slater KG.</emphasis> 2003. Comparison of PCR assays for detection of the agent of human granulocytic ehrlichiosis, <citetitle><emphasis>Anaplasma phagocytophilum. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41</emphasis><emphasis role="strong">:</emphasis>717–722.</para>
          </listitem>
          <listitem id="ch0085s0000li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">Sumner JW, Nicholson WL, Massung RF.</emphasis> 1997. PCR amplification and comparison of nucleotide sequences from the groESL heat shock operon of <citetitle><emphasis>Ehrlichia</emphasis></citetitle> species. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">35:</emphasis>2087–2092.</para>
          </listitem>
          <listitem id="ch0085s0000li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Bell CA, Patel R.</emphasis> 2005. A real-time combined polymerase chain reaction assay for the rapid detection and differentiation of <citetitle><emphasis>Anaplasma phagocytophilum</emphasis></citetitle>, <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle>, and <citetitle><emphasis>Ehrlichia ewingii. Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">53</emphasis><emphasis role="strong">:</emphasis>301–306.</para>
          </listitem>
          <listitem id="ch0085s0000li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">Buchan BW, Jobe DA, Mashock M, Gerstbrein D, Faron ML, Ledeboer NA, Callister SM.</emphasis> 2019. Evaluation of a novel multiplex high-definition PCR assay for detection of tick-borne pathogens in whole-blood specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">57:</emphasis>e00513-19.</para>
          </listitem>
          <listitem id="ch0085s0000li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">Anderson BE, Sumner JW, Dawson JE, Tzianabos T, Greene CR, Olson JG, Fishbein DB, Olsen-Rasmussen M, Holloway BP, George EH.</emphasis> 1992. Detection of the etiologic agent of human ehrlichiosis by polymerase chain reaction. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">30</emphasis><emphasis role="strong">:</emphasis>775–780.</para>
          </listitem>
          <listitem id="ch0085s0000li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Everett ED, Evans KA, Henry RB, McDonald G.</emphasis> 1994. Human ehrlichiosis in adults after tick exposure. Diagnosis using polymerase chain reaction. <citetitle><emphasis>Ann Intern Med</emphasis></citetitle> <emphasis role="strong">120</emphasis><emphasis role="strong">:</emphasis>730–735.</para>
          </listitem>
          <listitem id="ch0085s0000li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Chu FK.</emphasis> 1998. Rapid and sensitive PCR-based detection and differentiation of aetiologic agents of human granulocytotropic and monocytotropic ehrlichiosis. <citetitle><emphasis>Mol Cell Probes</emphasis></citetitle> <emphasis role="strong">12:</emphasis>93–99.</para>
          </listitem>
          <listitem id="ch0085s0000li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">Reller ME, Dumler JS.</emphasis> 2020. Optimization and evaluation of a multiplex quantitative PCR assay for detection of nucleic acids in human blood samples from patients with spotted fever rickettsiosis, typhus rickettsiosis, scrub typhus, monocytic ehrlichiosis, and granulocytic anaplasmosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>e01802-19.</para>
          </listitem>
          <listitem id="ch0085s0000li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">Doyle CK, Labruna MB, Breitschwerdt EB, Tang YW, Corstvet RE, Hegarty BC, Bloch KC, Li P, Walker DH, McBride JW.</emphasis> 2005. Detection of medically important <citetitle><emphasis>Ehrlichia</emphasis></citetitle> by quantitative multicolor TaqMan real-time polymerase chain reaction of the dsb gene. <citetitle><emphasis>J Mol Diagn</emphasis></citetitle> <emphasis role="strong">7</emphasis><emphasis role="strong">:</emphasis>504–510.</para>
          </listitem>
          <listitem id="ch0085s0000li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">Wagner ER, Bremer WG, Rikihisa Y, Ewing SA, Needham GR, Unver A, Wang X, Stich RW.</emphasis> 2004. Development of a p28-based PCR assay for <citetitle><emphasis>Ehrlichia chaffeensis. Mol Cell Probes</emphasis></citetitle> <emphasis role="strong">18</emphasis><emphasis role="strong">:</emphasis>111–116.</para>
          </listitem>
          <listitem id="ch0085s0000li0145" role="bibliographyEntry">
            <para>145.<emphasis role="strong">Rodino KG, Pritt BS.</emphasis> 2021. Novel applications of metagenomics for detection of tickborne pathogens. <citetitle><emphasis>Clin Chem</emphasis></citetitle> <emphasis role="strong">68:</emphasis>69–74.</para>
          </listitem>
          <listitem id="ch0085s0000li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Rodino KG, Wolf MJ, Sheldon S, Kingry LC, Petersen JM, Patel R, Pritt BS.</emphasis> 2021. Detection of tick-borne bacteria from whole blood using 16S ribosomal RNA gene PCR followed by next-generation sequencing. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>e03129-20.</para>
          </listitem>
          <listitem id="ch0085s0000li0147" role="bibliographyEntry">
            <para>147.<emphasis role="strong">Ravyn MD, Goodman JL, Kodner CB, Westad DK, Coleman LA, Engstrom SM, Nelson CM, Johnson RC.</emphasis> 1998. Immunodiagnosis of human granulocytic ehrlichiosis by using culture-derived human isolates. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>1480–1488.</para>
          </listitem>
          <listitem id="ch0085s0000li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Comer JA, Nicholson WL, Olson JG, Childs JE.</emphasis> 1999. Serologic testing for human granulocytic ehrlichiosis at a national referral center. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37</emphasis><emphasis role="strong">:</emphasis>558–564.</para>
          </listitem>
          <listitem id="ch0085s0000li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Aguero-Rosenfeld ME, Kalantarpour F, Baluch M, Horowitz HW, McKenna DF, Raffalli JT, Hsieh T, Wu J, Dumler JS, Wormser GP.</emphasis> 2000. Serology of culture-confirmed cases of human granulocytic ehrlichiosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38</emphasis><emphasis role="strong">:</emphasis>635–638.</para>
          </listitem>
          <listitem id="ch0085s0000li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">IJdo JW, Zhang Y, Hodzic E, Magnarelli LA, Wilson ML, Telford SR III, Barthold SW, Fikrig E.</emphasis> 1997. The early humoral response in human granulocytic ehrlichiosis. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">176</emphasis><emphasis role="strong">:</emphasis>687–692.</para>
          </listitem>
          <listitem id="ch0085s0000li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">Walls JJ, Aguero-Rosenfeld M, Bakken JS, Goodman JL, Hossain D, Johnson RC, Dumler JS.</emphasis> 1999. Inter- and intralaboratory comparison of <citetitle><emphasis>Ehrlichia equi</emphasis></citetitle> and human granulocytic ehrlichiosis (HGE) agent strains for serodiagnosis of HGE by the immunofluorescent-antibody test. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>2968–2973.</para>
          </listitem>
          <listitem id="ch0085s0000li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Stillman BA, Monn M, Liu J, Thatcher B, Foster P, Andrews B, Little S, Eberts M, Breitschwerdt EB, Beall MJ, Chandrashekar R.</emphasis> 2014. Performance of a commercially available in-clinic ELISA for detection of antibodies against <citetitle><emphasis>Anaplasma phagocytophilum</emphasis></citetitle>, <citetitle><emphasis>Anaplasma platys</emphasis></citetitle>, <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle>, <citetitle><emphasis>Ehrlichia canis</emphasis></citetitle>, and <citetitle><emphasis>Ehrlichia ewingii</emphasis></citetitle> and <citetitle><emphasis>Dirofilaria immitis</emphasis></citetitle> antigen in dogs. <citetitle><emphasis>J Am Vet Med Assoc</emphasis></citetitle> <emphasis role="strong">245:</emphasis>80–86.</para>
          </listitem>
          <listitem id="ch0085s0000li0153" role="bibliographyEntry">
            <para>153.<emphasis role="strong">Beall MJ, Chandrashekar R, Eberts MD, Cyr KE, Diniz PP, Mainville C, Hegarty BC, Crawford JM, Breitschwerdt EB.</emphasis> 2008. Serological and molecular prevalence of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle>, <citetitle><emphasis>Anaplasma phagocytophilum</emphasis></citetitle>, and <citetitle><emphasis>Ehrlichia</emphasis></citetitle> species in dogs from Minnesota. <citetitle><emphasis>Vector Borne Zoonotic Dis</emphasis></citetitle> <emphasis role="strong">8</emphasis><emphasis role="strong">:</emphasis>455–464.</para>
          </listitem>
          <listitem id="ch0085s0000li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 2008. Ehrlichiosis and anaplasmosis 2008 case definition. <ulink url="https://ndc.services.cdc.gov/case-definitions/ehrlichiosis-and-anaplasmosis-2008/">https://ndc.services.cdc.gov/case-definitions/ehrlichiosis-and-anaplasmosis-2008/</ulink>. Accessed 3 January 2018.</para>
          </listitem>
          <listitem id="ch0085s0000li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Bakken JS, Krueth J, Wilson-Nordskog C, Tilden RL, Asanovich K, Dumler JS.</emphasis> 1996. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. <citetitle><emphasis>JAMA</emphasis></citetitle> <emphasis role="strong">275</emphasis><emphasis role="strong">:</emphasis>199–205.</para>
          </listitem>
          <listitem id="ch0085s0000li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Bakken JS, Haller I, Riddell D, Walls JJ, Dumler JS.</emphasis> 2002. The serological response of patients infected with the agent of human granulocytic ehrlichiosis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">34:</emphasis>22–27.</para>
          </listitem>
          <listitem id="ch0085s0000li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Horowitz HW, Aguero-Rosenfeld ME, Holmgren D, McKenna D, Schwartz I, Cox ME, Wormser GP.</emphasis> 2013. Lyme disease and human granulocytic anaplasmosis coinfection: impact of case definition on coinfection rates and illness severity. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">56:</emphasis>93–99.</para>
          </listitem>
          <listitem id="ch0085s0000li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Diuk-Wasser MA, Vannier E, Krause PJ.</emphasis> 2016. Coinfection by Ixodes tick-borne pathogens: ecological, epidemiological, and clinical consequences. <citetitle><emphasis>Trends Parasitol</emphasis></citetitle> <emphasis role="strong">32:</emphasis>30–42.</para>
          </listitem>
          <listitem id="ch0085s0000li0159" role="bibliographyEntry">
            <para>159.<emphasis role="strong">Magnarelli LA, Dumler JS, Anderson JF, Johnson RC, Fikrig E.</emphasis> 1995. Coexistence of antibodies to tick-borne pathogens of babesiosis, ehrlichiosis, and Lyme borreliosis in human sera. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>3054–3057.</para>
          </listitem>
          <listitem id="ch0085s0000li0160" role="bibliographyEntry">
            <para>160.<emphasis role="strong">Wong SJ, Thomas JA.</emphasis> 1998. Cytoplasmic, nuclear, and platelet autoantibodies in human granulocytic ehrlichiosis patients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>1959–1963.</para>
          </listitem>
          <listitem id="ch0085s0000li0161" role="bibliographyEntry">
            <anchor id="ch0085s0000a0065"/>
            <para>161.<emphasis role="strong">Asanovich KM, Bakken JS, Madigan JE, Aguero-Rosenfeld M, Wormser GP, Dumler JS.</emphasis> 1997. Antigenic diversity of granulocytic <citetitle><emphasis>Ehrlichia</emphasis></citetitle> isolates from humans in Wisconsin and New York and a horse in California. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">176:</emphasis>1029–1034.</para>
          </listitem>
          <listitem id="ch0085s0000li0162" role="bibliographyEntry">
            <para>162.<emphasis role="strong">Dawson JE, Fishbein DB, Eng TR, Redus MA, Green NR.</emphasis> 1990. Diagnosis of human ehrlichiosis with the indirect fluorescent antibody test: kinetics and specificity. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">162:</emphasis>91–95.</para>
          </listitem>
          <listitem id="ch0085s0000li0163" role="bibliographyEntry">
            <para>163.<emphasis role="strong">Yu XJ, Crocquet-Valdes P, Cullman LC, Walker DH.</emphasis> 1996. The recombinant 120-kilodalton protein of <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle>, a potential diagnostic tool. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">34:</emphasis>2853–2855.</para>
          </listitem>
          <listitem id="ch0085s0000li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Luo T, Zhang X, Nicholson WL, Zhu B, McBride JW.</emphasis> 2010. Molecular characterization of antibody epitopes of <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> ankyrin protein 200 and tandem repeat protein 47 and evaluation of synthetic immunodeterminants for serodiagnosis of human monocytotropic ehrlichiosis. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">17:</emphasis>87–97.</para>
          </listitem>
          <listitem id="ch0085s0000li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Chikeka I, Matute AJ, Dumler JS, Woods CW, Mayorga O, Reller ME.</emphasis> 2016. Use of peptide-based enzyme-linked immunosorbent assay followed by immunofluorescence assay to document <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> as a cause of febrile illness in Nicaragua. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>1581–1585.</para>
          </listitem>
          <listitem id="ch0085s0000li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">Childs JE, Sumner JW, Nicholson WL, Massung RF, Standaert SM, Paddock CD.</emphasis> 1999. Outcome of diagnostic tests using samples from patients with culture-proven human monocytic ehrlichiosis: implications for surveillance. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>2997–3000.</para>
          </listitem>
          <listitem id="ch0085s0000li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Wong SJ, Brady GS, Dumler JS.</emphasis> 1997. Serological responses to <citetitle><emphasis>Ehrlichia equi</emphasis></citetitle>, <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle>, and <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> in patients from New York State. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">35:</emphasis>2198–2205.</para>
          </listitem>
          <listitem id="ch0085s0000li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Chen SM, Yu XJ, Popov VL, Westerman EL, Hamilton FG, Walker DH.</emphasis> 1997. Genetic and antigenic diversity of <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle>: comparative analysis of a novel human strain from Oklahoma and previously isolated strains. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">175</emphasis><emphasis role="strong">:</emphasis>856–863.</para>
          </listitem>
          <listitem id="ch0085s0000li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Roland WE, McDonald G, Caldwell CW, Everett ED.</emphasis> 1995. Ehrlichiosis—a cause of prolonged fever. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">20</emphasis><emphasis role="strong">:</emphasis>821–825.</para>
          </listitem>
          <listitem id="ch0085s0000li0170" role="bibliographyEntry">
            <para>170.<emphasis role="strong">Dumler JS, Chen SM, Asanovich K, Trigiani E, Popov VL, Walker DH.</emphasis> 1995. Isolation and characterization of a new strain of <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle> from a patient with nearly fatal monocytic ehrlichiosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>1704–1711.</para>
          </listitem>
          <listitem id="ch0085s0000li0171" role="bibliographyEntry">
            <para>171.<emphasis role="strong">Todd SR, Dahlgren FS, Traeger MS, Beltrán-Aguilar ED, Marianos DW, Hamilton C, McQuiston JH, Regan JJ.</emphasis> 2015. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain spotted fever. <citetitle><emphasis>J Pediatr</emphasis></citetitle> <emphasis role="strong">166:</emphasis>1246–1251.</para>
          </listitem>
          <listitem id="ch0085s0000li0172" role="bibliographyEntry">
            <para>172.<emphasis role="strong">Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, Auwaerter PG, Baldwin K, Bannuru RR, Belani KK, Bowie WR, Branda JA, Clifford DB, DiMario FJ Jr, Halperin JJ, Krause PJ, Lavergne V, Liang MH, Meissner HC, Nigrovic LE, Nocton JJJ, Osani MC, Pruitt AA, Rips J, Rosenfeld LE, Savoy ML, Sood SK, Steere AC, Strle F, Sundel R, Tsao J, Vaysbrot EE, Wormser GP, Zemel LS.</emphasis> 2021. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis and treatment of Lyme disease. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">72:</emphasis>e1–e48.</para>
          </listitem>
          <listitem id="ch0085s0000li0173" role="bibliographyEntry">
            <para>173.<emphasis role="strong">Branger S, Rolain JM, Raoult D.</emphasis> 2004. Evaluation of antibiotic susceptibilities of <citetitle><emphasis>Ehrlichia canis</emphasis></citetitle>, <citetitle><emphasis>Ehrlichia chaffeensis</emphasis></citetitle>, and <citetitle><emphasis>Anaplasma phagocytophilum</emphasis></citetitle> by real-time PCR. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">48:</emphasis>4822–4828.</para>
          </listitem>
          <listitem id="ch0085s0000li0174" role="bibliographyEntry">
            <para>174.<emphasis role="strong">Brouqui P, Raoult D.</emphasis> 1992. In vitro antibiotic susceptibility of the newly recognized agent of ehrlichiosis in humans, <citetitle><emphasis>Ehrlichia chaffeensis. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">36:</emphasis>2799–2803.</para>
          </listitem>
          <listitem id="ch0085s0000li0175" role="bibliographyEntry">
            <para>175.<emphasis role="strong">Horowitz HW, Hsieh TC, Aguero-Rosenfeld ME, Kalantarpour F, Chowdhury I, Wormser GP, Wu JM.</emphasis> 2001. Antimicrobial susceptibility of <citetitle><emphasis>Ehrlichia phagocytophila. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">45</emphasis><emphasis role="strong">:</emphasis>786–788.</para>
          </listitem>
          <listitem id="ch0085s0000li0176" role="bibliographyEntry">
            <para>176.<emphasis role="strong">Klein MB, Nelson CM, Goodman JL.</emphasis> 1997. Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: promising activity of quinolones and rifamycins. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">41:</emphasis>76–79.</para>
          </listitem>
          <listitem id="ch0085s0000li0177" role="bibliographyEntry">
            <para>177.<emphasis role="strong">Maurin M, Bakken JS, Dumler JS.</emphasis> 2003. Antibiotic susceptibilities of <citetitle><emphasis>Anaplasma</emphasis></citetitle> (<citetitle><emphasis>Ehrlichia</emphasis></citetitle>) <citetitle><emphasis>phagocytophilum</emphasis></citetitle> strains from various geographic areas in the United States. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">47</emphasis><emphasis role="strong">:</emphasis>413–415.</para>
          </listitem>
          <listitem id="ch0085s0000li0178" role="bibliographyEntry">
            <para>178.<emphasis role="strong">Buitrago MI, Ijdo JW, Rinaudo P, Simon H, Copel J, Gadbaw J, Heimer R, Fikrig E, Bia FJ.</emphasis> 1998. Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">27</emphasis><emphasis role="strong">:</emphasis>213–215.</para>
          </listitem>
          <listitem id="ch0085s0000li0179" role="bibliographyEntry">
            <para>179.<emphasis role="strong">Wormser GP, Filozov A, Telford SR III, Utpat S, Kamer RS, Liveris D, Wang G, Zentmaier L, Schwartz I, Aguero-Rosenfeld ME.</emphasis> 2006. Dissociation between inhibition and killing by levofloxacin in human granulocytic anaplasmosis. <citetitle><emphasis>Vector Borne Zoonotic Dis</emphasis></citetitle> <emphasis role="strong">6</emphasis><emphasis role="strong">:</emphasis>388–394.</para>
          </listitem>
          <listitem id="ch0085s0000li0180" role="bibliographyEntry">
            <para>180.<emphasis role="strong">Krause PJ, Corrow CL, Bakken JS.</emphasis> 2003. Successful treatment of human granulocytic ehrlichiosis in children using rifampin. <citetitle><emphasis>Pediatrics</emphasis></citetitle> <emphasis role="strong">112:</emphasis>e252–e253.</para>
          </listitem>
          <listitem id="ch0085s0000li0181" role="bibliographyEntry">
            <para>181.<emphasis role="strong">Dumler JS, Bakken JS.</emphasis> 1996. Human granulocytic ehrlichiosis in Wisconsin and Minnesota: a frequent infection with the potential for persistence. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">173:</emphasis>1027–1030.</para>
          </listitem>
          <listitem id="ch0085s0000li0182" role="bibliographyEntry">
            <para>182.<emphasis role="strong">Dumler JS, Sutker WL, Walker DH.</emphasis> 1993. Persistent infection with <citetitle><emphasis>Ehrlichia chaffeensis. Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">17</emphasis><emphasis role="strong">:</emphasis>903–905.</para>
          </listitem>
          <listitem id="ch0085s0000li0183" role="bibliographyEntry">
            <para>183.<emphasis role="strong">des Vignes F, Piesman J, Heffernan R, Schulze TL, Stafford KC III, Fish D.</emphasis> 2001. Effect of tick removal on transmission of <citetitle><emphasis>Borrelia burgdorferi</emphasis></citetitle> and <citetitle><emphasis>Ehrlichia phagocytophila</emphasis></citetitle> by <citetitle><emphasis>Ixodes scapularis</emphasis></citetitle> nymphs. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">183</emphasis><emphasis role="strong">:</emphasis>773–778.</para>
          </listitem>
          <listitem id="ch0085s0000li0184" role="bibliographyEntry">
            <para>184.<emphasis role="strong">Pekova S, Vydra J, Kabickova H, Frankova S, Haugvicova R, Mazal O, Cmejla R, Hardekopf DW, Jancuskova T, Kozak T.</emphasis> 2011. <citetitle><emphasis>Candidatus</emphasis></citetitle> Neoehrlichia mikurensis infection identified in 2 hematooncologic patients: benefit of molecular techniques for rare pathogen detection. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">69</emphasis><emphasis role="strong">:</emphasis>266–270.</para>
          </listitem>
          <listitem id="ch0085s0000li0185" role="bibliographyEntry">
            <para>185.<emphasis role="strong">Centers for Disease Control and Prevention.</emphasis> 2021. National Notifiable Diseases Surveillance System (NNDSS). Surveillance case definitions for current and historical conditions. <ulink url="https://ndc.services.cdc.gov/">https://ndc.services.cdc.gov/</ulink>.</para>
          </listitem>
        </itemizedlist>
        <anchor id="ch0085s0000a0062"/>
        <beginpage pagenum="1308"/>
      </sect2>
    </sect1>
  </chapter>
